Composition for personal care and its use

专利摘要:
skin care compositions. A personal care composition is provided comprising: at least a first phase and a second phase, said first phase comprising a) an aqueous structured surfactant phase comprising stns (sodium tridecet sulfate, where n is the average number of moles of ethoxylate per molecule) where n is from about 0 to about 2.5, b), c) a structuring system comprising: i. optionally a nonionic emulsifier, ii. optionally a nonionic emulsifier, ii. optionally from about 0.05% to about 5% by weight of said personal care composition of an associative polymer, iii. an electrolyte, and said second phase comprises a) a benefit phase comprising from 1% to about 50% by weight of said personal care composition of a hydrophobic benefit agent.
公开号:BR112012031623B1
申请号:R112012031623-0
申请日:2011-06-10
公开日:2018-04-10
发明作者:Shiqing Wei Karl；Dewey Smith Edward Iii；Lynn Mansfield Shawn；Herbert Koenig Peter；Ji Wei；Suradkar Yogesh；Bagchi Deepa；Logou Sujatha；David Jones Stevan
申请人:The Procter & Gamble Company；
IPC主号:

专利说明:

(54) Title: COMPOSITION FOR PERSONAL CARE AND ITS USE (51) Int.CI .: A61K 8/19; A61K 8/02; A61K 8/31; A61K 8/46; A61K 8/92; A61Q 19/10; A61K 8/39; A61K 8/41; A61K 8/44; A61K 8/81; C08L 33/08; 1/11 C11D; A61K 8/06 (52) CPC: A61K 8/19, A61K 8/02, A61K 8/31, A61K 8/463, A61K 8/92, A61Q 19/10, A61K 8/39, A61K 8/41, A61K 8/44, A61K 8/81, C08L 33/08, C11D 1/29, A61K 8/062 (30) Unionist Priority: 11/06/2010 US 61 / 354,118 (73) Holder (s): THE PROCTER & GAMBLE COMPANY (72) Inventor (s): KARL SHIQING WEI; EDWARD DEWEY SMITH III; SHAWN LYNN MANSFIELD; PETER HERBERT KOENIG; WEI JI; YOGESH SURADKAR; DEEPA BAGCHI; SUJATHA LOGOU; STEVAN DAVID JONES
1/77
COMPOSITION FOR PERSONAL CARE AND ITS USE
BACKGROUND OF THE INVENTION [001] Cleansing the skin is an activity that has been carried out for millennia. Over time, skin cleansing and methods related to skin cleansing have involved the use of soap, surfactants and the like. Nowadays, a prevalent form of skin cleansing compositions is the liquid form, often known as liquid body soap. Users of liquid body soap appreciate the conveniences offered by these compositions, but the experience is not ideal. Although skin cleansing compositions have evolved, the problems associated with these compositions have not. Many of the problems associated with current skin cleansing compositions and methods, particularly liquid body soap compositions, have not been resolved, and remain to this day as problems for users of these products.
[002] Structured surfactant compositions are commercially useful for suspending or stabilizing dispersions, particularly dispersions of beneficial agents which can be particles, domains, phases, emulsions and the like. Structured compositions can be manufactured, packaged and delivered to the user without losing their physical integrity and aesthetics.
[003] There are many ways to obtain structure, including surfactant phases, gel networks, crystalline domains, physical gels, polymeric structurants and polymer gels of various types, as well as particle networks and the like. Structured surfactants are a useful way of obtaining structure, since the surfactant has the dual function of providing stability to the composition and offering foaming, cleanliness, smoothness and other functions typically associated with surfactants. This is efficient, low cost and simple.
Petition 870180007766, of 01/29/2018, p. 6/88
2/77 [004] An important function of the surfactant is its ability to provide structure, in an undiluted state, as part of a personal hygiene composition. However, a second function of the surfactant requires that, after dilution, the personal care composition transitions quickly to free surfactant micelles, which foam and clean. The need to provide an adequate structure when in an undiluted state, and to become micellar after dilution has not been recognized in the art.
[005] Modern personal care compositions, including liquid body soaps, use surfactants, such as sodium tridecet-3 sulfate (ST3S). Although these surfactants demonstrate good cleaning efficiency and are commercially successful, they have intrinsic problems associated with their use, specifically related to their ability to offer structuring, the nature of which is often cascading. Typically, large amounts of ST3S need to be present to adequately stabilize any personal hygiene composition of which it is a part, since lower concentrations result in unstable products, which are not acceptable to the consumer. Furthermore, the high levels of surfactant make it difficult to form smooth compositions. To reinforce the structure, it is often necessary to use alkyl sulfates or coconut monoethanol amide, however these compositions reduce smoothness. Consequently, personal care compositions that have higher concentrations for stability tend to be aggressive to the skin. Efforts are made to add benefit agents to these compositions, with variations in success, since large relative amounts of benefit agents are required, which often creates instability. Furthermore, due to the large amount of surfactant, many beneficial agents are not readily
Petition 870180007766, of 01/29/2018, p. 7/88
3/77 compatible within the tolerances allowed by the need to use surfactants to obtain stability. Finally, attempts made to compensate for the above conditions often result in unacceptable foaming properties. These problems have been systemic in both single-phase and multi-phase compositions, since surfactant concentrations in domains containing surfactants have resulted in compositions that no longer offer a superior consumer experience. In addition, the compositions can also be overly structured, resulting in unsatisfactory performance and foaming.
[006] Protection of the environment is also a growing concern. Thus, there is an additional desire to reduce the amount of surfactants contained in the products. The reduction in the amount of surfactants in personal care compositions is hampered by the need to maintain the effectiveness of the benefit agents contained therein.
[007] There is, therefore, a need for a personal care composition that offers superior cleaning performance without the negative elements previously associated with liquid body soaps, including high concentrations of surfactant, aggressiveness, stability problems and compatibility problems. .
SUMMARY OF THE INVENTION [008] One aspect of the present invention relates to a personal care composition comprising: at least a first phase and a second phase, wherein: said first phase comprises: a) an aqueous structured surfactant phase , comprising from about 5% to about 20%, by weight of said personal care composition, in STnS, where n is between about 0.5 and about 2.7, b)
Petition 870180007766, of 01/29/2018, p. 8/88
4/77 at least one of the following: an amphoteric surfactant and a zwitterionic surfactant, c) a structuring system comprising: i. optionally, a nonionic emulsifier, ii. optionally, from about 0.05% to about 5%, by weight of said personal care composition, of an associative polymer, iii. an electrolyte, and said second phase comprises: a) a benefit phase comprising from 0.1% to about 50%, by weight of said personal care composition, of a hydrophobic benefit agent, said composition for personal care is optionally substantially free of LSS, said personal care composition comprising at least a 70% lamellar structure.
BRIEF DESCRIPTION OF THE DRAWINGS [009] Figure 1 is a graph of the dissolution of compositions in the STnS series.
[0010] Figure 2 is a graph of the rheology profile of compositions in the STnS series.
[0011] Figure 3 is a graph of Young's Module of compositions of the STnS series.
[0012] Figure 4 is a graph capturing the highest dilution that kept 100% of the lamellar volume.
[0013] Figure 5 is a graph of the phase transition during the dilution of compositions of the STnS series.
[0014] Figure 6 is a graph of the volume of the lamellar phase during the dilution level of an ST2S composition with different co-active agents.
[0015] Figure 7 is a graph of the rheology profile of STnS compositions with different associative polymers. [0016] Figure 8 is a graph of the clinical benefits of hydration.
[0017] Figure 9 is a graph of the DPD Curvature of compositions of the STnS series.
[0018] Figure 10 is an illustration to determine the volume of the third phase.
Petition 870180007766, of 01/29/2018, p. 9/88
5/77 invention, the term means that the components and / or
DETAILED DESCRIPTION OF THE INVENTION [0019] Although the specification ends with the claims that particularly point and distinctly claim the invention, it is believed that the present invention will be better understood from the description below.
[0020] The devices, apparatus, methods, components and / or compositions of the present invention may include, consist essentially of, or consist of the components of the present invention, as well as other ingredients described herein. For use herein consisting essentially of devices, devices, methods, compositions may include additional ingredients, but only so long as they do not substantially alter the basic and innovative characteristics of the claimed devices, devices, methods, components and / or compositions.
[0021] All percentages and ratios used in the present invention are expressed by weight of the total composition, and all measurements are made at 25 ° C, unless otherwise noted.
[0022] All measurements used in the present invention are in metric units, unless otherwise specified.
[0023] The term anhydrous, for use in the present invention, except where otherwise indicated, refers to those compositions or materials containing less than about 10%, more preferably less than about 5%, still less than about 3% and, preferably, zero percent by weight of water.
[0024] The term multiphase for use in the present invention means that the compositions comprise at least two phases that are chemically distinct (for example, a surfactant phase and a benefit phase). These phases are over with more
Petition 870180007766, of 01/29/2018, p. 10/88
6/77 in direct physical contact with each other and are not separated by a barrier. In one aspect of the invention, the personal care composition can be a multiphase personal care composition in which the phases of the personal care composition are mixed or mixed to a significant degree. In another aspect of the invention, the personal care composition may be a multiphase personal care composition in which the phases of the personal care composition are placed so as to occupy separate but distinct physical spaces within the package in which they are stored, but are in direct contact with each other (that is, they are not separated by a barrier and are not emulsified or mixed to any significant degree).
[0025] The term packaging includes any container suitable for personal care compositions that exhibit a viscosity of about 1,500 centipoise (cP) to about 1,000,000 cP, including, but not limited to, a bottle, an inverted plastic tube, a tube, a pitcher, a non-aerosol pump and mixtures thereof.
[0026] The term personal care composition, for use in the present invention, refers to compositions intended for topical application to the skin or hair. The compositions of the present invention are rinse-off formulations, in which the product is applied topically to the skin or hair and then, after a few minutes, is subsequently rinsed with water from the skin or hair or otherwise removed using a substrate, with deposition of a portion of the composition. The compositions can also be used as shaving or hair removal aids. The personal care composition of the present invention can typically be extruded or dispensed from a package. Multiphase personal care compositions typically exhibit a viscosity of about 1,500 centipoise (cP) to about 1,000,000 cP, as
Petition 870180007766, of 01/29/2018, p. 11/88
7/77 measured by the Viscosity Determination Method described in the common property patent application published on November 11, 2004 as US publication No. 2004 / 0223991A1, entitled Multi-phase Personal Care Compositions and filed on May 7, 2004 by Wei, et al. The multiphase personal care compositions of the present invention can be in the form of liquid, semi-liquid, cream, lotion or gel compositions for topical application to the skin. Examples of personal care compositions of the present invention may include, but are not limited to, shampoo, conditioning shampoo, liquid body soap, liquid body moisturizing soap, shower gels, skin cleansing creams, cleansing milks, soaps liquids for hair and body, body moisturizer for use in the bath, shampoo for pets, shaving or waxing preparations and cleaning compositions used in conjunction with a disposable cleaning cloth.
[0027] The term substantially free of, for use in the present invention means, except where otherwise indicated, that the composition includes less than about 5%, preferably less than about 3%, more preferably less than about 1 % and, most preferably, less than about 0.1% of the mentioned ingredient. For use in the present invention, the term exempt from means that the composition comprises 0% of the mentioned ingredient, that is, the ingredient has not been added to the composition, but may incidentally form as a by-product or as a reaction product of other components composition. [0028] For use in the present invention, the term stable means that the multiphase personal care composition comprises less than 10% by volume of the third phase, more preferably less than 5% by volume of the third phase, with the most preference less than 1% by volume of the third phase after being submitted to
Petition 870180007766, of 01/29/2018, p. 12/88
8/77 rapid aging protocol and measurement of the third phase, as described below in the Method for determining the third phase.
[0029] For use in the present invention, the term structured means having a rheology that gives stability to the composition of multiple phases. The degree of structure is determined by characteristics determined by one or more of the following methods: the Young's modulus method, the elastic limit method, the zero shear rate viscosity method, or the ultracentrifugation method, all presented in the Test Methods section, below. Consequently, a surfactant phase of the multiphase composition of the present invention is considered to be structured if the surfactant phase has one or more of the following properties described below, according to the Young's Modulus Method, the Elastic Limit Method, the Viscosity method under zero shear rate or the Ultracentrifugation method. A surfactant phase is considered structured if the phase has one or more of the following characteristics:
[0030] A. a Viscosity under zero shear rate of
at least about in 100 Pascal-seconds (Pa-s), alternatively fur any less fence in 200 Pa.s, alternatively fur any less fence in 500 Pa.s, alternatively fur any less fence of 1 .000 Pa.s, alternatively fur least about 1,500 Pa.s, or alternatively at least fence 2,000 Pa.s, or [0031] B. a reason between structured domain volumes
as measured by the ultracentrifugation method described later in this document, of more than about 40%, preferably at least about 45%, more preferably at least about 50%, more preferably at least about 55%, with more preferably at least about 60%, more preferably at least about 65%, with more
Petition 870180007766, of 01/29/2018, p. 13/88
9/77 preferably at least about 70%, more preferably at least about 75%, most preferably at least about 80%, most preferably at least about 85% or, most preferably, at least about 90%. [0032] C. a Young's Modulus greater than about 2 Pascals (Pa), with more preference greater than about 10 Pa, with more preference even greater than about 20 Pa, with more preference even greater than about 30 Pa , 40 Pa, 50 Pa, 75 Pa or, with the most preference, greater than 100 Pa.
[0033] For use in the present invention, the term surfactant component means the total of all anionic, nonionic, amphoteric, zwiterionic and cationic surfactants present in one phase. When calculations are based on the surfactant component, water and electrolyte are excluded from calculations involving the surfactant component, since surfactants as manufactured are typically diluted and neutralized.
[0034] For use in the present invention, the term STnS means sodium tridecet sulfate, where n is defined as the average number of moles of ethoxylate per molecule. Tridecet is a 13-carbon branched ethoxylated hydrocarbon that comprises, in one embodiment, an average of at least 1 methyl branch per molecule.
[0035] For use in the present invention, the term LSS means sodium lauryl sulfate.
[0036] For use in the present invention, the term foam means aerated foam that results from the application of energy to aqueous mixtures of surfactant, especially diluted mixtures. Foaming is increased in micellar compositions as compared to structured compositions, for example lamellar, so that a phase change during dilution for micelles typically increases foaming.
[0037] For use in the present invention inverted plastic tube refers to a bottle that rests on its
Petition 870180007766, of 01/29/2018, p. 14/88
10/77 neck or mouth, through which its contents are filled and dispensed, but which is also the end on which the said bottle is intended to rest or rest (for example, the base of the bottle) for storage by the consumer and / or for display on the store shelf (this bottle is referred to in this document as an inverted plastic tube). Typically, the cap of an inverted plastic tube is flat or concave, so that said tube can, when stored, rest on said cap. Suitable inverted plastic tubes are described in copending US patent application serial number 11/067443, filed on February 25, 2005 by McCall, et al, and entitled Multi-phase Personal Care Compositions, Process for Making and Providing, and Article of Commerce.
[0038] For use in the present invention, the term visually distinct refers to a region of the multiphase personal care composition that has a medium composition, in the sense that it is distinct from another region that has a different average composition, in which the regions are visible to the naked eye. This does not prevent the distinct regions from comprising two similar phases, in which one phase could comprise pigments, dyes, particles and several optional ingredients, consequently forming a region of different average composition. A phase generally occupies one or more spaces with larger dimensions than the colloidal or subcolloidal components comprised by it. A phase can also be constituted or reconstituted, collected or separated into a phase volume, so that its properties can be observed, for example by means of centrifugation, filtration or the like.
[0039] One embodiment of the present invention relates to a personal care composition comprising: at least a first phase and a second phase, said first phase comprising an aqueous structured surfactant phase comprising a) of about 5 % about
Petition 870180007766, of 01/29/2018, p. 15/88
11/77 of 20%, by weight of said personal care composition, of STnS, where n is between about 1.2 and about 2.7, b) an amphoteric surfactant, c) a structuring system comprising: i. optionally, a nonionic emulsifier, ii. optionally, from about 0.05% to about 5%, by weight of said personal care composition, of an associative polymer, iii. an electrolyte, and said second phase comprises a) a benefit phase comprising from 1% to about 50%, by weight of said personal care composition, of a hydrophobic benefit agent, said personal care composition being optionally substantially free of LSS, said aqueous surfactant phase comprising at least 70% of a structured phase, preferably a lamellar phase.
[0040] Without sticking to the theory, it is believed that the surprising and unexpected results produced by the personal care compositions of the present invention eliminate the problems associated with personal care compositions. Specifically, it was found that the use of STnS, where n is less than 3, allows an increase in structuring at low concentrations. This structure allows to obtain an improved stability with lower levels of surfactant. The reduction in the amount of surfactant optimizes the compatibility of the benefit agents contained in the personal care compositions. The optimized capacity allows additional benefit agents to be used in increased amounts. The reduction in the amount of surfactant, together with the increased capacity of the beneficial agents, provides an increase in the smoothness of the personal care compositions. Finally, the improved structure allows to obtain an optimized foam formation with higher levels of dilution, since the micellar phase (where the foam can be formed) occurs at a higher level of dilution.
[0041] Cleaning phase
Petition 870180007766, of 01/29/2018, p. 16/88
12/77 [0042] One of the phases of the personal care composition of the present invention is a cleaning phase, which is a surfactant phase. The cleaning phase consists of a structured domain that comprises a surfactant and, optionally, a co-surfactant. The structured domain is preferably an opaque structured domain, which is preferably a lamellar phase. The lamellar phase can offer shear resistance, adequate yield for the suspension of particles and droplets and, at the same time, provide long-term stability, since it is thermodynamically stable. The lamellar phase tends to have a viscosity that minimizes the need for viscosity modifiers. [0043] The surfactant of the present invention is sodium tridecet (n) sulfate, from this point on in this document called STnS, where n defines the moles of ethoxylation. In one embodiment, n is in the range of more than 0 to 3, alternatively from 0.5 to 2.7, alternatively from 1.1 to 2.5, alternatively from more than 0 to 2.5, alternatively from 1.8 to 2.2, or alternatively about 2. It should be understood that a material like ST2S, for example, can comprise a significant amount of molecules that have no ethoxylate, 1 mole of ethoxylate, 3 moles of ethoxylate, and so on. onwards, in a distribution that can be wide, narrow or truncated, also comprising ST2S, where the average of the distribution is about 2.
[0044] In one embodiment, the personal care compositions of the present invention comprise from about 3% to
fence in 20% in STnS, alternatively in fence in 5% a fence in 15% in STnS, alternatively in fence in 7% a fence in 13% in STnS, alternatively in fence in 5% a fence in 13% STnS or, alternatively , in fence in 1% a
about 13% of STnS.
[0045] It has been found that STnS having less than 3 moles of ethoxylation offers structural improvements
Petition 870180007766, of 01/29/2018, p. 17/88
Surprising 13/77. Figure 5 illustrates these improvements by comparing a composition that comprises ST1S, ST2S and ST3S. At increased dilution levels, ST3S begins to transition from a lamellar structure to a micellar structure, starting with a surfactant content of around 19%. Thus, dilution beyond this level results in a loss of structure. This loss of structure has, until now, required higher concentrations of surfactant to be present inside a package. Compositions with ST2S can remain well structured up to a 13% dilution point of surfactant in this example, allowing the transition to a more micellar structure at much higher dilution levels. Compositions with ST1S can remain lamellar even at lower concentrations of surfactant.
[0046] Although sodium tridecet sulfate has been presented and marketed, the use and benefits of sodium tridecet sulfate having lower ethoxylation values were unknown, a basis further supported by the wide general acceptance of ST3S in commercially available products, and the lack of commercial availability of products with lower ethoxylation. It is this unknown and surprising result that allows the various benefits of the personal care compositions of the present invention, including improved stability, smoothness, compatibility and foaming.
[0047] Without sticking to the theory, the basis for the enhanced function of STnS, where n is below 3, can be illustrated with the use of simulations of dissipative particle dynamics (DPD). With regard to STnS, the surfactant aggregates form curved surfaces based on the shape of the surfactant and the interactions between molecules, leading to surfactant architectures that are phases, and to a degree of phase structure as measured by rheology parameters , as viscosity under zero shear rate.
Petition 870180007766, of 01/29/2018, p. 18/88
14/77
To measure the amount of curvature of the surfactant, molecular simulations were performed with the use of DPD, by breaking up surfactant atoms in microspheres, where a microsphere typically represents 3 to 4 heavy atoms. The simulations were carried out in a cubic cell with an edge length of approximately 25 nm. The compositions of the simulation boxes varied in mean amount of ethoxylation (n = 0 to 3) of the STnS. During the course of the simulations, the assembly of surfactants in aggregates was observed, starting from random positions. The DPD curvature was calculated as an average curvature over multiple independent simulations for the polar group of the surfactant-water surface of all the resulting objects in a simulation table, including all bilayers and micelles, being a relative measure of the deviation mean of the colligative surface of the polar group of the surfactant from the plane. The DPD curvature of zero consists of flat layers with edge defects, which do not form multilamellar vesicles and, therefore, are not expected to exhibit structured rheology, for example, high viscosity at zero shear rate. At a DPD curvature of about 0.07 and greater, the formation of elongated micellar structures is observed. At an intermediate DPD curvature, curved bilayers can form multilamellar vesicles, leading to high viscosity under zero shear rate and stable compositions.
[0048] As illustrated in Figure 9, the simulation results demonstrate that bilayers formed from STnS compositions have a lower DPD curvature of surfactant aggregates with decreasing n. The DPD curvature of ST0S compositions is too low to form compact vesicle structures, while the DPD curvature of ST3S compositions is too high, so that the viscosity under shear rate
Petition 870180007766, of 01/29/2018, p. 19/88
15/77 zero is not so high compared to ST2S compositions of the present invention. The preferred structure is observed for compositions of the present invention having a DPD curvature between about 0.03 and 0.045.
[0049] Often, STnS is combined with LSS to form a surfactant system. In one embodiment, the personal care compositions of the present invention comprise less than about 5% LSS, alternatively less than about 4% LSS, alternatively less than about 3% LSS, alternatively less than about 2% LSS. LSS, alternatively less than about 1% LSS, alternatively between about 0.1% LSS and about 2% LSS or, alternatively, about 0% LSS. Without sticking to the theory, the presence of LSS is believed to increase the aggressiveness of the personal care composition, at least in part invalidating the softness benefits and / or the effectiveness of the benefit agents contained in the personal care composition.
[0050] Cotensoativo [0051] The personal care compositions of the present invention additionally comprise a cotensoativo. The co-surfactants in the present invention comprise from about 0.1% to 20%, alternatively from about 2% to about 10% of the personal care composition. The co-surfactants of the present invention comprise amphoteric surfactants, zwitterionic surfactants and mixtures thereof. In one embodiment, the personal care composition comprises at least one amphoteric surfactant and / or at least one zwitterionic surfactant. Amphoteric surfactants suitable for use in the present invention include those that are widely described as derived from secondary and tertiary aliphatic amines in which the aliphatic radical can be a straight or branched chain, and where one of the aliphatic substituents contains from about 8 to about of 18 carbon atoms, and one contains a group
Petition 870180007766, of 01/29/2018, p. 20/88
16/77 solubilizing in anionic water, for example carboxy, sulfonate, sulfate, phosphate or phosphonate. Examples of compounds that fall within this definition are sodium 3-dodecyl amino propionate, sodium 3-dodecyl amino propane sulfonate, sodium lauryl sarcosinate, N-alkyl taurines like that prepared by reacting dodecyl amine with sodium isethionate, as described in US Patent No. 2,658,072, N-alkyl aspartic acids, such as those produced in accordance with US Patent No. 2,438,091, and the products described in US Patent No. 2,528,378 . In one aspect, the multi-stage personal care composition may comprise an amphoteric surfactant that is selected from the group consisting of sodium lauran anfoacetate, sodium cocoanfoacetate, disodium lauroanfoacetate, disodium cocodianfoacetate and mixtures thereof. In addition, amphoacetates and dianfoacetates can also be used.
[0052] The zwitterionic surfactants suitable for use in the composition include those that are widely described as derivatives of aliphatic quaternary ammonium, phosphonium and sulfonium compound, in which the aliphatic radicals can be straight chain branched, and are characterized by the fact that a of the aliphatic substituents contains from about 8 to about 18 carbon atoms, and one contains a carboxy, sulfonate, sulfate group. Zwiterionic surfactants suitable for use in the multi-stage personal care composition include betaines, including propyl betaine cocoamido.
[0053] Associative polymer [0054] In one embodiment, the associative polymer is a cross-linked associative polymer, expandable by alkali, comprising acid monomers and associative monomers with hydrophobic end groups, so that the anionic polymer, phosphate, for example, or phosphonate .
Petition 870180007766, of 01/29/2018, p. 21/88
17/77 comprises a percentage of hydrophobic modification and a hydrophobic side chain comprising functional alkyl groups of a length. Without sticking to the theory, it is believed that acid monomers contribute to the polymer's ability to expand in water by neutralizing acid groups, and associative monomers anchor the polymer in structured hydrophobic surfactant domains, for example lamellae, to impart structure to the surfactant compositions and prevent the polymer from falling apart and lose effectiveness in the presence of electrolytes. The cross-linked associative polymer comprises a percentage of hydrophobic modification, which is the molar percentage of monomers expressed as a percentage of the total number of all monomers in the main polymer chain, including both acidic and other non-acidic monomers. The percentage of hydrophobic modification of the polymer, later in this document called% HM, can be determined by the ratio between monomers added during synthesis, or by analytical techniques such as proton nuclear magnetic resonance (NMR). The length of the alkyl side chain can be determined in a similar way. Monomers comprising only 2 or less alkyl hydrocarbons (for example ethyl, methyl) are not considered associative for the purposes of the present invention, with all side chains having more than 2 carbons being associative. The associative alkyl side chains comprise, for example, butyl, propyl, stearyl, estearet, cetyl, lauryl, lauret, octyl, beenila, beenet, estearet or other linear, branched, saturated or unsaturated alkyl hydrocarbon or chain side chains.
[0055] Cross-linked associative polymers, having a preferred% HM and preferential carbon numbers of the hydrophobic end groups of the alkyl side chains have been found to offer optimizations
Petition 870180007766, of 01/29/2018, p. 22/88
18/77 of structure to the structured surfactant compositions of the present invention, especially to the compositions of the invention comprising reduced levels of surfactant, providing said structure in surprisingly low levels of polymer structurant. Concentrations of associative polymer of up to 5% or even 10% are shown in the art to obtain a sufficient amount of structure, for example the exemplary compositions of US Patent No. 7,119,059 (Librizzi, et al) and 6,897,253 ( Schmucker-Castner, et al). The inventors found that when the% HM of the associative polymer and the number of carbons in the alkyl side chain are optimized, the structure of the aqueous structured surfactant phase is increased with the use of only less than 3% by weight of polymer associative as a percentage of the aqueous structured surfactant phase, preferably less than 2%, more preferably less than 1%, and even only about 0.2% of the phase, as demonstrated by the examples of the invention presented later in this document .
[0056] The acid monomer can comprise any acid functional group, for example sulfate, sulfonate, carboxylate, phosphonate or phosphate, or mixtures of acid groups. In one embodiment, the acidic monomer comprises a carboxylate, alternatively the acidic monomer is an acrylate, including acrylic acid and / or methacrylic acid. The acid monomer comprises a polymerizable structure, for example vinyl functionality. Mixtures of acidic monomers, for example mixtures of acrylic acid and methacrylic acid monomers, are useful.
[0057] The associative monomer comprises a hydrophobic terminal group and a polymerizable component, for example vinyl, which are bonded together. The hydrophobic end group can be linked to the polymerizable component, and from this to the polymer chain, by different means, but
Petition 870180007766, of 01/29/2018, p. 23/88
19/77 is preferably linked by an ether, ester, or amide functionality, such as an alkyl acrylate or vinyl alkanoate monomer. The hydrophobic end group can also be separated from the chain, for example by an alkoxy ligand, such as an alkyl ether. In one embodiment, the associative monomer is an alkyl ester, alternatively an alkyl (meth) acrylate, where (meth) acrylate is understood as methyl acrylate, acrylate, or mixtures of the two. [0058] In one embodiment, the hydrophobic end group of the associative polymer is incompatible with the aqueous phase of the composition, and is associated with the hydrophobic foaming surfactant components of the present invention. Without sticking to the theory, it is believed that the longer alkyl chains of the terminal groups of the hydrophobic structuring polymer increase the incompatibility with the aqueous phase to accentuate the structure, while the somewhat shorter alkyl chains having carbon numbers that are they look a lot like those of hydrophobic foaming surfactants (eg 12 to 14 carbons) or multiples thereof (for bilayers, for example) are also effective, so a range of preferred materials is ideal balancing these opposing, limited requirements by the solubility of the total molecule itself. Polymers having short alkyl side chains, for example with less than 6 carbons, are ineffective for the present invention. The inventors found that an ideal range of carbon numbers for the hydrophobic end group, combined with an optimum percentage of hydrophobic monomers expressed as a percentage of the polymer backbone, provides an increased structure to the foaming structured surfactant composition at low structurant levels. polymeric.
[0059] Preferred associative polymers comprise about C16 (cetyl) hydrophobic alkyl side chains with about 0.7% hydrophobic modification, but the
Petition 870180007766, of 01/29/2018, p. 24/88
20/77 percentage of hydrophobic modification can be up to the limit of aqueous solubility in surfactant compositions, for example up to 2%, or 5%, or 10%. An exemplary preferred associative polymer is the Aqupec SER-300, available from Sumitomo Seika, Japan, which consists of cross-polymer acrylates / alkyl acrylate C10-30 and comprises stearyl side chains with less than about 1% HM . Other preferred associative polymers comprise side chains of stearyl, octyl, decyl and lauryl. The preferred associative polymers are Aqupec SER-150 (cross polymer of acrylates / C10-30 alkyl acrylates) comprising about C18 (stearyl) side chains and about 0.4% HM, and Aqupec HV-701EDR, which comprises about C8 (octyl) side chains and about 3.5% HM. Another preferred polymer is Stabylen 30, produced by 3V Sigma S.p.A., which has branched side chains of associative hydrophobic isodecanoate. It is important to note that the inventors have found that not all crosslinked associative polymers are effective, and that many are harmful to the structure. Associative polymers having hydrophobic side chains with less than 7 carbons and having a% HM greater than about 25% or about 50% are non-preferred. For example, Carbopol Aqua SF-1 (crosslinked acrylate copolymer) having an average alkyl side chain with 4.5 carbons and more than 50% HM is harmful to the structure, as demonstrated by the examples presented later in this document.
[0060] Deposition polymers [0061] The personal care compositions of the present invention may additionally comprise an organic cationic deposition polymer in one or more phases, as a deposition aid for the beneficial agents described herein. Cationic deposition polymers suitable for use in the compositions of the present invention contain portions
Petition 870180007766, of 01/29/2018, p. 25/88
21/77 nitrogen-containing cations, such as portions of quaternary ammonium. Some non-limiting examples of cationic deposition polymers for use in the personal hygiene composition include polysaccharide polymers, such as cationic cellulose derivatives. The preferred cationic cellulose polymers are the hydroxyl ethyl cellulose salts reacted with trimethyl ammonium substituted epoxide, cited in the industry (CTFA) as Polyquaternium 10, and which are available from Amerchol Corp. (Edison, N.J., USA) in their Polymer KG, JR and LR series polymers, with KG-30M being the most preferred. Other suitable cationic deposition polymers include derivatives of cationic guar gum, such as guar hydroxy propyl triammonium chloride, of which specific examples include the series
Jaguar (preferably Jaguar C-17), commercially available from Rhodia Inc., and the N-Hance polymer series, commercially available from Aqualon.
[0062] In one embodiment, the deposition polymers of the present invention have a cationic charge density of about 0.8 meq / g to about 2.0 meq / g, alternatively about 1.0 meq / g to about 1.5 meq / g.
[0063] Water [0064] The surfactant phase of the present invention also comprises water. In one embodiment, the surfactant phase of the personal care composition comprises from about 10% to about 90%, alternatively from about 40% to about 85%, alternatively from about 60% to about 80%, in weight, water.
[0065] Benefit phase [0066] The personal care compositions of the present invention comprise a benefit phase. The benefit phase in the present invention is preferably hydrophobic or essentially anhydrous, and can be substantially free of water. The benefit phase can be free or substantially free of surfactant.
Petition 870180007766, of 01/29/2018, p. 26/88
22/77 [0067] The benefit phase typically comprises benefit agents. Benefit agents include water insoluble or hydrophobic benefit agents. The benefit phase may comprise from about 0.1% to about 50%, preferably from about 1% to about 30%, more preferably from about 5% to about 30%, by weight of the composition for personal care, from a benefit agent.
[0068] The hydrophobic skin benefit agent for use in the benefit phase of the composition has a Vaughan solubility (PSV) parameter of about 5 to about 15, preferably about 5 to less than 10. These solubility parameters are well known in the formulation technique, and are defined in Vaughan in Cosmetics and Toiletries, Vol. 103, pgs. 47-69, October 1988.
[0069] Some non-limiting examples of glycerides suitable for use as hydrophobic beneficial agents for the skin in the present invention include castor oil, soybean oil, derivatized soybean oils such as malted soybean oil, safflower oil, stone oil cotton, corn oil, walnut oil, peanut oil, olive oil, cod liver oil, almond oil, avocado oil, babassu oil and sesame oil, vegetable oils, sunflower seed oil, and derivatives of vegetable oil, coconut oil and derivatized coconut oil, cottonseed oil and derivatized cottonseed oil, jojoba oil, cocoa butter and combinations thereof.
Some non-limiting examples of acetoglyceride esters suitable for use as hydrophobic skin benefit agents in the present invention include acetylated monoglycerides.
[0071] Some non-limiting examples of alkyl esters suitable for use as hydrophobic beneficial agents for the skin in the present invention include isopropyl fatty acid esters and chain esters
Petition 870180007766, of 01/29/2018, p. 27/88
23/77 long chain fatty acids (i.e., C10-C24), for example cetyl ricinoleate, of which some non-limiting examples include isopropyl palmitate, isopropyl myristate, cetyl ricinoleate and stearyl ricinoleate. Other examples are: hexyl laurate, isohexyl laurate, myristyl myristate, isohexyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, isopropyl isostearate, diisopropyl adipate, diisopropylate adipate diexil decila, diisopropyl sebacate, acyl isononanoate lauryl lactate, myristyl lactate, cetyl lactate and combinations of these substances.
[0072] Some non-limiting examples of alkenyl esters suitable for use as hydrophobic skin benefit agents in the present invention include oleyl myristate, oleyl stearate, oleyl oleate and combinations of these substances.
[0073] Some non-limiting examples of polyglycerin fatty acid esters suitable for use as hydrophobic beneficial agents for the skin in the present invention include decaglyceryl distearate, decaglyceryl diiso-stearate, decaglyceryl monomyriate, decaglyceryl monolaurate, hexaglyceride monooleate, hexaglyceride, hexaglyceride glycerol monooleate combinations thereof.
[0074] Some non-limiting examples of lanolin and lanolin derivatives suitable for use as hydrophobic skin benefit agents in the present invention include lanolin, lanolin oil, lanolin wax, lanolin alcohols, lanolin fatty acid, lanolin isopropyl, acetylated lanolin, acetylated lanolin alcohols, lanolin alcohol linoleate, lanolin alcohol ricinoleate and combinations of these substances.
[0075] Some non-limiting examples of silicone oils suitable for use as beneficial agents for the
Petition 870180007766, of 01/29/2018, p. 28/88
Hydrophobic skin in the present invention include dimethicone copolyol, dimethyl polysiloxane, diethyl polysiloxane, mixed C1-C30 alkyl polysiloxanes, phenyl dimethicone, dimethicone and combinations of these substances. Preferred are non-volatile silicones selected from dimethicone, dimethicone, C1-C30 mixed alkyl polysiloxane and combinations of these substances. Some non-limiting examples of silicone oils used herein are described in U.S. Patent No. 5,011,681 (Ciotti et al.).
[0076] Other suitable hydrophobic skin benefit agents include milk triglycerides (e.g., hydroxylated milk glyceride) and polyol fatty acid polyesters.
[0077] Other suitable hydrophobic skin benefit vehicles include wax esters, some non-limiting examples of which include beeswax and beeswax derivatives, spermaceti, myristyl myristate, stearyl stearate and combinations of these substances . Vegetable waxes such as carnauba and candelilla waxes, sterols such as cholesterol, cholesterol fatty acid esters, and phospholipids such as lecithin and derivatives, sphingolipids, ceramides, glycosphingolipids and combinations thereof, are also useful. Beneficial agents that are also suitable include glycerol monooleate.
[0078] Active ingredients for the skin and solid particles [0079] The compositions can optionally comprise the skin benefit ingredients presented below, to obtain an optimized application of these benefit materials on the skin.
[0080] A) Active flaking [0081] The active flaking components enhance the skin-looking benefits offered by this
Petition 870180007766, of 01/29/2018, p. 29/88
25/77 invention. The active components of peeling tend, for example, to improve skin texture (for example, smoothness). A peeling system that is suitable for use in the present invention contains sulfhydryl compounds and zwitterionic surfactants, and is described in U.S. Patent No. 5,681,852, issued to Bissett. Preferred concentrations of peeling assets are in the range of about 0.1% to about 10%, more preferably from about 0.2% to about 5% and, most preferably, from about 0.5% to about 4%, by weight of the personal hygiene composition.
[0082] Another peeling system that is suitable for use in the present invention contains salicylic acid and zwitterionic surfactants, and is described in U.S. Patent No. 5,652,228, issued to Bissett. Zwitterionic surfactants, such as those described in these patent applications, are also usable here as peeling agents, with cetyl betaine being particularly preferred.
[0083] B) Anti-wrinkle actives / Anti-atrophy actives [0084] Anti-wrinkle actives or anti-atrophy actives include sulfur-containing amino acids D and L, as well as their derivatives and salts, particularly Nacetyl derivatives. A preferred example is N-acetyl-L-cysteine, thiols, for example ethane thiol, hydroxy acids (for example, alpha hydroxy acids such as lactic acid and glycolic acid or beta hydroxy acids such as salicylic acid and salicylic acid derivatives such as the octanoyl derivative), phytic acid, lipoic acid, lysophosphatidic acid, and skin peeling agents (eg, phenol and the like).
[0085] Hydroxy acids as active agents for the skin in the present invention include salicylic acid and salicylic acid derivatives, with the preferred concentrations of anti-wrinkle / anti-atrophy actives being in the range of about 0.01% about 50%, with more
Petition 870180007766, of 01/29/2018, p. 30/88
26/77 preferably from about 0.1% to about 10% and, most preferably, from about 0.5% to about 2%, by weight of the personal hygiene composition.
[0086] Other non-limiting examples of anti-wrinkle assets suitable for use in the present invention are described in U.S. Patent No. 6,217,888, issued to Oblong et al. [0087] C) Antioxidants / radical scavengers [0088] Some non-limiting examples of antioxidants or radical scavengers for use in the present invention include ascorbic acid and its salts, ascorbyl fatty acid esters, derivatives of ascorbic acid (e.g. magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol, tocopherol acetate, other tocopherol esters, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethyl chromanic-2- carboxylic acid (commercially available under the trade name Trolox®), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its alkyl salts and esters, sorbic acid and its salts, lipoic acid, amines (for example, N, N-diethyl hydroxylamine, amino-guanidine), sulfhydryl compounds (eg, glutathione), fumaric dihydroxy acid and its salts, licine pidolate, arginine pidolate, nordihydro-hydroxy acid, bioflavonoids, curcumin, lysine , methionine, proline, superoxide dismutase, silymarin, tea extracts, grape peel / seed extracts, melanin and rosemary extracts. Preferred concentrations are in the range of about 0.1% to about 10% and, more preferably, from about 1% to about 5%, by weight of the personal hygiene composition.
[0089] D) Chelators [0090] The term chelating or chelating agent refers to those active agents for the skin capable of removing a metal ion from a system by forming a
Petition 870180007766, of 01/29/2018, p. 31/88
27/77 about 10% about 5%, complex, so that the metal ion cannot readily participate in, or catalyze, chemical reactions.
[0091] Chelating agents, as active agents for the skin for use in the present invention, are preferably formulated at concentrations in the range of about 0.1% a, and more preferably, about 1% a by weight of the composition for personal hygiene.
Some non-limiting examples of suitable chelating agents are described in US patent No. 5,487,884, issued 1/30/96 to Bissett et al., International publication No. 91/16035 by Bush et al., Published on 10/31 / 95, and international publication No. 91/16034 by Bush et al., Published on 10/31/95.
[0092] A preferred chelating agent for use in the compositions of the present invention includes disodium EDTA and derivatives thereof.
[0093] E) Anti-cellulite agents [0094] Some non-limiting examples of anti-cellulite agents include xanthine compounds such as caffeine, theophylline, theobromine, aminophylline and combinations of these items. Anti-cellulite agents are preferably included in concentrations ranging from about 0.1% to about 10%, more preferably from about 1% to about 5%, by weight of the personal hygiene composition.
[0095] F) Tanning assets [0096] Some non-limiting examples of these tanning agents include dihydroacetone, also known as DHA or 1,3-dihydroxy-2-propanone. Tanning assets are preferably included in concentrations in the range of about 0.1% to about 10% and, more preferably, from about 1% to about 5%, by weight of the personal hygiene composition .
[0097] G) Skin whitening agents [0098] Some non-limiting examples of skin whitening agents suitable for use in the present invention
Petition 870180007766, of 01/29/2018, p. 32/88
28/77 include cojic acid, arbutin, ascorbic acid and derivatives of these substances (eg magnesium ascorbyl phosphate or sodium ascorbyl phosphate), as well as extracts (eg blackberry extract, placenta extract). Some non-limiting examples of skin lightening agents suitable for use in the present invention also include those described in WO 95/34280, WO 95/07432 and WO 95/23780. Skin bleaching agents are preferably included in concentrations in the range of about 0.1% to about 10%, more preferably from about 1% to about 5%, by weight of the personal hygiene composition.
[0099] H) Skin softening and healing actives [00100] Some non-limiting examples of skin softening or healing actives, suitable for use in the present invention, include derivatives of panthenic acid (eg, panthenol, dexpanthenol, ethyl panthenol), aloe vera, allantoin, bisabolol and dipotassium glycyrrhizinate. The soothing and healing actives for the skin are preferably included in concentrations in the range of about 0.1% to about 10% and, more preferably, from about 1% to about 5%, by weight. composition for personal hygiene.
[00101] I) Microbicidal assets [00102] Some non-limiting examples of microbicidal assets for use in the present invention include β-lactam-based drugs, quinolone-based drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, ether 2 , 4,4'-trichloro-2'-diphenyl hydroxy, 3,4,4'-trichlorobanilide, phenoxy ethanol, phenoxy propanol, phenoxy isopropanol, doxycycline, capreomycin, chlorhexidine, chlorotetracycline, oxytetracycline, clindamycin, ethambutidine, hexamide isethylate. metronidazole, pentamidine, metacycline, gentamicin, methenamine, kanamycin, minocycline, linomycin, neomycin,
Petition 870180007766, of 01/29/2018, p. 33/88
29/77 netilmycin, paromomycin, streptomycin, tobramycin,
miconazole, hydrochloride tetracycline, erythromycin, zinc erythromycin, estolato in erythromycin, stearate in erythromycin, sulfate in amikacin, hydrochloride in doxycycline, sulfate in capreomycin, gluconate in chlorhexidine, hydrochloride in chlorhexidine, hydrochloride in
chlorotetracycline, oxytetracycline hydrochloride, clindamycin hydrochloride, ethambutol hydrochloride, metronidazole hydrochloride, pentamidine hydrochloride, gentamicin sulphate, kanamycin sulfate, linomycin hydrochloride, metacycline hydrochloride, methylenate hydrochloride, mandelin hydrochloride, mandelin neomycin sulphate, netilmycin sulphate, paromomycin sulphate, streptomycin sulphate, tobramycin sulphate, miconazole hydrochloride, ketoconazole, amanfadine hydrochloride, amanfadine sulphate, octopirox, parachloromethaxylenol, nystatin, tolnaftate, also zinc, tolnaftate, zinc zinc salt such as zinc carbonate), clotrimazole and combinations thereof.
[00103] Microbicides are preferably included in concentrations in the range of about 0.1% to about 10% and, more preferably, from about 1% to about 5%, by weight of the hygiene composition folks.
[00104] J) Sunscreen assets [00105] Some non-limiting examples of organic or inorganic sunscreen assets for use in the present invention are described below. Among the inorganic sunscreens useful to the present invention are metal oxides such as titanium dioxide with an average main particle size of about 15 nm to about 100 nm, zinc oxide with an average main particle size of about 15 nm at about 150 nm, zirconium oxide with an average main particle size of about 15 nm at about 150 nm and iron oxide with a
Petition 870180007766, of 01/29/2018, p. 34/88
30/77 average main particle size of about 15 nm to about 500 nm, as well as mixtures of these substances. [00106] The concentration of the active sunscreen for use in the composition, preferably is in the range of about 0.1% to about 20% and, more typically, from about 0.5% to about 10% , by weight of the composition. The exact amounts of these assets will vary according to the sunscreen or sunscreens chosen, and the desired sun protection factor (SPF).
[00107] A wide variety of conventional organic sunscreen actives are also suitable for use in the present invention, some non-limiting examples of which include p-aminobenzoic acid, its salts and derivatives (ethyl, isobutyl and glyceryl esters, p- dimethylaminobenzoic), anthranilates (ie, o-amino-benzoates, methyl, menthyl, phenyl, benzyl, phenyl ethyl, linally, terpinyl and cyclohexenyl esters), salicylates (amyl, esters, phenyl, octyl, glyceryl and glycyl esters, glyceryl, glyceryl, glyceryl and glycyl. di-propylene glycols), cinnamic acid derivatives (menthyl and benzyl esters, α-phenyl cinamonitrile, cinnamyl butyl pyruvate), cinnamic dihydroxy acid derivatives (umbeliferone, methyl umbeliferone, methyl aceto umbeliferone), trihydroxyninic acid derivatives (esculetin, methyl esculetin, dafnetina and the glycosides esculin and dafnina), hydrocarbons (diphenyl butadiene, stilbene), dibenzal acetone and benzal acetophen on, naphthol sulfonates (sodium salts of 2naphthol-3,6-disulfonic and 2-naphthol-6,8-disulfonic acids), dihydroxynaphonic acid and its salts, o and p-hydroxy biphenyl disulfonates, coumarin derivatives (7-hydroxy , 7-methyl, 3-phenyl), diazoles (2-acetyl-3-bromoindazole, phenyl benzoxazole, methyl naphthoxazole, various aryl benzothiazoles), quinine salts (bisulfate, sulfate, chloride, oleate and tannate), quinoline derivatives ( 8-hydroxy salts
Petition 870180007766, of 01/29/2018, p. 35/88
31/77 quinoline, 2-phenyl quinoline), hydroxy or methoxy substituted benzophenone, uric and violuric acids, tannic acid and its derivatives (eg hexaethyl ether), ether (butyl carbotol) (6-propyl piperonyl), hydroquinone, benzophenones (oxybenzene, sulisobenzone, dioxy benzone, benzoresescincinol, 2,2 ', 4,4'-tetrahydroxy benzophenone, 2,2'dihydroxy-4,4'-dimethoxy benzophenone, octabenzone, 4isopropyl dibenzoyl methane, butyl methoxy dibenzoyl methane, ethanol , octocrylene, [3- (4'-methyl benzylidene bornan-2one), terephthalylidene dicphorous sulfonic acid and 4isopropyl-di-benzoyl methane. Among these sunscreens, 2-ethyl hexyl-p-methoxy cinnamate (commercially available as PARSOL MCX), 4,4'-t-butyl methoxy dibenzoyl methane (commercially available as PARSOL 1789), 2-hydroxy-4-methoxy benzophenone, octyl dimethyl-p-amino benzoic acid, digaloyl trileate, 2,2-dihydroxy-4 -methoxy benzophenone, ethyl-4- (bis (hydroxy propyl)) amino benzoate, 2-ethyl hexyl-2-cyano-3,3 -diphenyl acrylate, ethyl hexyl 2-salicylate, glyceryl-p-amino benzoate, 3,3,5-methyl cyclohexyl tri-salicylate, methyl anthranylate, p-dimethyl-amino benzoic acid or amino benzoate, 2-ethyl dimethyl hexyl-p-amino benzoate, 2-phenyl benzimidazole-5-sulfonic acid, 2- (p-dimethyl amino phenyl) -5-sulfoxybenzoic acid, octocrylene and combinations of these substances.
[00108] K) Solid particulates [00109] The compositions of the present invention can comprise a solid particle. Some non-limiting examples of solid particles include: interference pigment, multilayer pigment, metallic particle, solid and liquid crystals, or combinations of these items.
[00110] An interference pigment is a pearl-gloss pigment, prepared by coating the surface of a particle substrate material with a
Petition 870180007766, of 01/29/2018, p. 36/88
32/77 thin film. The particle substrate material generally has a platelet shape. The thin film is a transparent or semi-transparent material, with a high refractive index. The material with a high refractive index has a pearlescent luster, resulting from the mutual interference action between the reflection of the incident light at the interface of the substrate / platelet coating layers, and the reflection of the incident light on the surface of the coating layer. The interference pigments of the multi-stage personal care compositions preferably comprise no more than about 20%, more preferably not more than about 10%, more preferably not more than about 7% and, with even more preferably, no more than about 5%, by weight, of said composition. The interference pigment of the multi-stage personal care composition preferably comprises at least about 0.1%, more preferably at least about 0.2%, most preferably at least about 0.5 with more more and, preferably, at least about 1% by weight of the composition. When the pigment is applied and rinsed as described in the Method for determining the deposition of pigments via tape removal, as described in the copending order with serial number 60 / 469,075, deposited on May 8, 2003, the amount of pigment deposited on the skin it is preferably at least 0.5 pg / cm2, more preferably at least 1 pg / cm2 and most preferably at least 5 pg / cm2.
[00111] In one embodiment of the present invention, the surface of the interfering pigment is either hydrophobic, or has been hydrophobically modified. The Particle Contact Angle Test, as described in the order with serial number 60 / 469,075, deposited on May 8, 2003, is used to determine the contact angle of the pigments
Petition 870180007766, of 01/29/2018, p. 37/88
33/77 interference. The greater the contact angle, the greater the hydrophobic capacity of the interference pigment. The interference pigment of the present invention has a contact angle of at least 60 degrees, more preferably greater than 80 degrees, more preferably even greater than 100 degrees, more preferably even greater than 100 degrees. The hydrophobically modified interference pigment, or PIHM, allows its trapping inside the phases, and a greater deposition of said PIHM. The ratio between the PIHM and a phase is preferably from 1: 1 to about 1:70, more preferably from 1: 2 to about 1:50, most preferably from 1: 3 to about 1 : 40 and, most preferably, from 1: 7 to about 1:35.
[00112] In an embodiment of the present invention, HIPCs are preferably trapped within the benefit phase. This requires that the particle size of the benefit phase is generally larger than the PIHM. In a preferred embodiment of the invention, the particles of the benefit phase contain only a small number of PIHMs per benefit particles. Preferably, this number is less than 20, more preferably less than 10 and, most preferably, less than 5. These parameters, the relative size of the benefit droplets in relation to PIHM and the approximate number of particles of PIHM per Benefit particles can be determined using visual inspection with light microscopy.
[00113] The PIHM and the benefit phase can be mixed to the composition, by means of a pre-mixture or separately. In the case of separate addition, the hydrophobic pigments divide in the benefit phase during the processing of the formulation. The PIHM of the present invention preferably has a hydrophobic coating comprising no more than about 20%, more preferably no more than about 15% and, most preferably, no more than about 10% by weight, of the total weight of the particle. The PIHM
Petition 870180007766, of 01/29/2018, p. 38/88
34/77 of the present invention preferably has a hydrophobic coating comprising at least about 0.1%, more preferably at least about 0.5% and, most preferably, at least about 1% by weight , of the total particle weight. Some non-limiting examples of the hydrophobic surface treatments used herein include silicones, silicone and acrylate copolymers, acrylate polymers, alkyl silane, isopropyl titanium triiso stearate, sodium stearate, magnesium myristate, perfluoroalcohol phosphate, polymethyl isopropyl ether, lecithin, carnauba wax, polyethylene, chitosan, lauroyl lysine, vegetable lipid extracts and mixtures of these items, preferably silicones, silanes and stearates. Surface treatment manufacturers include US Cosmetics, KOBO Products Inc. and Cardre Inc. [00114] Optional ingredients [00115] Although not essential for the purposes of the present invention, the materials on the non-limiting list, in addition to the optional materials previously presented , illustrated later in this document, are suitable for use in the personal care composition, and can desirably be incorporated in certain modalities, for example to assist or optimize cleaning performance, for skin treatment, or to modify the composition's aesthetics to personal care, as is the case with perfumes, dyes, dyes or similar. Optional materials useful for the products of the present invention are categorized or described for their cosmetic and / or therapeutic benefit, or for their purported mode of action or function. However, it must be understood that the asset and the other materials usable here may, in some cases, offer more than one function or more than one cosmetic and / or therapeutic benefit, or operate through more than one mode of action. Therefore, the classifications made here are for convenience purposes only and should not limit the
Petition 870180007766, of 01/29/2018, p. 39/88
35/77 use of the ingredient application, or applications, particularly indicated (s). The exact nature of these optional materials, as well as their levels of incorporation, will depend on the physical form of the composition and the nature of the cleaning operation for which it will be used. Optional materials are generally formulated to less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1%, less than about 0.5%, less than about 0.25%, less than about 0.1%, less than about 0.01%, or less than about 0.005% of the personal care composition.
[00116] To further optimize stability under stress conditions, such as high temperature and vibration, it is preferable to adjust the densities of the separate phases so that they are substantially equal. To achieve this effect, low density microspheres can be added to one or more phases of the personal care composition, preferably to the structured surfactant phase. Personal care compositions comprising low density microspheres are described in a patent application published on May 13, 2004 under US patent publication 2004 / 0092415A1, entitled Striped Liquid Personal Cleansing Compositions Containing A Cleansing Phase and A Separate Phase with Improved Stability, and deposited on October 31, 2003 by Focht, et al.
[00117] Other optional non-limiting ingredients that can be used in the personal care composition of the present invention may comprise an optional beneficial component that is selected from the group consisting of thickening agents, preservatives, microbicides, fragrances, chelators (such as those described in US patent No. 5,487,884 issued to Bisset, et al., sequestrants, vitamins (for example, Retinol), vitamin derivatives (for example tocopheryl acetate, niacinamide, panthenol), sunscreens, peeling actives (such as those
Petition 870180007766, of 01/29/2018, p. 40/88
36/77 described in US patents No. 5,681,852 and 5,652,228 issued to Bisset), anti-wrinkle / anti-atrophy actives (for example N-acetyl derivatives, thiols, hydroxy acids, phenol), antioxidants (for example example ascorbic acid derivatives, tocopherol), skin softening agents / skin curing agents (e.g. pantenoic acid derivatives, aloe vera, allantoin), skin bleaching agents (e.g. cojic acid, arbutin, ascorbic acid derivatives) , skin tanning agents (for example dihydroxy acetone), anti-acne drugs, essential oils, sensory elements, pigments, colorants, pearlizing agents, interference pigments (for example as those presented in US patent No. 6,395,691 granted to Liang Sheng Tsaur, in US patent No. 6,645,511 granted to Aronson, et al., In US patent No. 6,759,376 granted to Zhang, et al, in US patent No. 6,780,826 granted to Zhang, et al.) Particles (eg talc, kaolin, mica, smectite clay, cellulose powder, polysiloxane, silicas, carbonates, titanium dioxide, polyethylene microspheres), particles with a different shape than hydrophobically modified platelets (for example hydrophobically modified titanium dioxide and other materials described in a common proprietary patent application published on August 17, 2006 under publication number 2006 / 0182699A, entitled Personal Care Compositions Containing Hydrophobically Modified Non-platelet particle and deposited on February 15, 2005 by Taylor, et al.) and mixtures thereof. In one aspect, the multiphase personal care composition can comprise from about 0.1% to about 4%, by weight of the multiphase personal care composition, of hydrophobically modified titanium dioxide. Other optional ingredients are, more typically, those materials approved for use in cosmetics, which are described in the CTFA Cosmetic manual
Petition 870180007766, of 01/29/2018, p. 41/88
37/77
Ingredient Handbook, Second Edition, The Cosmetic, Toiletries, and Fragrance Association, Inc. 1988, 1992. [00118] Test methods [00119] The present invention uses a number of test methods to determine various metrics of the structure. The methodology for these tests and the associated examples are illustrated below.
[00120] Methods of viscosity under zero shear rate and Young's modulus [00121] The viscosity under zero shear rate of a material that is a phase or a composition of the present composition can be measured before combining it with the composition, after preparing a composition, or first separating a phase or component of a composition by suitable means of physical separation, such as centrifugation, pipetting, mechanical cutting, rinsing, filtration, or other means of separation.
[00122] A voltage controlled rheometer such as a TA Instruments AR2000 rheometer is used to determine viscosity under zero shear rate. The determination is carried out at 25 ° C, with the measurement system by parallel plate with 4 cm in diameter, and a gap of 1 mm. The geometry has a shear stress factor of 79580 m-3 to convert the torque obtained into the stress. Serrated plates can be used to obtain consistent results when slipping occurs.
[00123] First the material is positioned on the base plate of the rheometer, then the measurement geometry (upper plate) is moved to its position 1.1 mm above the base plate. Excess material at the edge of the geometry is scraped off after locking the geometry. The geometry is then moved to the target position 1 mm above the base plate, with a pause of about 2 minutes to allow the relaxation of the load stresses. This charging procedure ensures that no voltage
Petition 870180007766, of 01/29/2018, p. 42/88
38/77 tangential is loaded at the beginning of the measurement, which can influence the results obtained. If the material comprises particles discernible to the naked eye or by tactile sensation (microspheres, for example), which are larger than about 150 microns in average numerical diameter, the adjustment of the gap between the base plate and the upper plate is increased to the less than 4 mm or 8 times the diameter of the 95th percentile volume of the particle diameter. If a phase has any particle larger than 5 mm in any dimension, the particles are removed before measurement.
[00124] The measurement is carried out by applying a continuous shear stress ramp from 0.1 Pa to 1,000 Pa over a 4 minute time interval using a logarithmic progression, that is, with points of measurement evenly spaced on a logarithmic scale. Thirty (30) measuring points per series of ten effort increases are obtained. If the measurement result is incomplete, for example if it is observed that the material flows from the gap, the results obtained are evaluated to the exclusion of incomplete data points. If there are insufficient points to obtain an accurate measurement, the measurement is repeated with an increased number of sampling points.
[00125] Young's Modulus (Pa) is obtained by plotting a Stress (Pa) versus Deformation (dimensionless) graph, and obtaining the slope of the regression line of the initial linear region between Stress and Deformation, which occurs typically in the region below about 4% deformation. If the relationship is not linear, the slope of the linear regression line below 2% deformation is taken as the Young's modulus (Pa), using the dimensionless deformation.
[00126] Viscosity at zero shear rate is obtained by taking a first median viscosity value
Petition 870180007766, of 01/29/2018, p. 43/88
39/77 in Pascal-seconds (Pa-s) for viscosity data obtained between, and even, 0.1 Pa and the point at which the viscosity starts to decline sharply. After writing down the first median viscosity, all viscosity values greater than 5 times the first median value and less than 0.2x the median value are excluded, and a second median viscosity value is obtained from the same viscosity data, excluding the indicated data points. The second median viscosity obtained in this way is the viscosity at zero shear rate.
[00127] The compositions of the present invention have a viscosity under zero shear rate of at least about 100 Pa-s, alternatively at least about 300 Pa-s, alternatively at least about 500 Pa-s, alternatively at least about 1,000 Pa-s, alternatively at least about 1,500 Pa-s or, alternatively, at least about 2,000 Pa-s.
[00128] The compositions of the present invention have a Young's modulus of at least about 2 Pa, alternatively at least about 5 Pa, alternatively at least about
10 Pa, alternatively fur any less fence in 20 Pan, alternatively fur any less fence in 30 Pan, alternatively fur any less fence in 40 Pan, alternatively fur any less fence in 50 Pan or,
alternatively, at least about 75 Pa.
[00129] Ultracentrifugation method [00130] The ultracentrifugation method is a physical method used to determine the amount of structure in a composition or in a subset of a composition. The method is also used to determine the rate at which a structured surfactant composition dissolves, after dilution to present effective amounts of surfactant to the cleaning environment proximal to the surfaces.
[00131] A composition is separated by ultracentrifuge into separate but distinguishable layers. The composition
Petition 870180007766, of 01/29/2018, p. 44/88
The multiphase personal care 40/77 of the present invention can have multiple distinguishable layers (for example, a structured surfactant layer and a benefit layer).
[00132] First, dispense about 4 grams of composition in a Beckman centrifuge tube (11 x 60 mm), until the tube is filled. Then, dilute the composition to a 10% dilution level using 90% of the composition and 10% deionized water, using a suitable mixer, and dispense the same amount of composition in a similar centrifuge tube. Continue diluting the composition and filling tubes in the same way, until a dilution level of 60% is obtained for the composition, using 40% of the composition with 60% deionized water. Place the centrifuge tubes in an ultracentrifuge (Beckman model L8-M or equivalent) using a belt rotor, and ultracentrifuge using the following conditions: 50,000 rpm, 2 hours, and 40 ° C.
[00133] Measure the relative phase volumes of the composition phases, by measuring the height of each layer with
the use of one caliber digital electronic (with precision in 0.01 mm). At layers are identified hair knowledgeable at technique per techniques of observation physics allies The
chemical identification, if necessary. For example, the structured surfactant layer is identified, for the present invention, by transmission electron microscopy (TEM), polarized light microscopy, and / or X-ray diffraction, as a structured lamellar phase comprising multilamellar vesicles, and the layer hydrophobic benefit is identified by its low moisture content (less than 10% water, as measured by Karl Fischer titration). The total height Ha, which includes all materials in the ultracentrifuge tube, is measured. Then, the height of each layer is measured from the bottom of the centrifuge tube to the top of the layer, and the extent of each layer is
Petition 870180007766, of 01/29/2018, p. 45/88
41/77 determined algebraically by subtraction. The benefit layer can comprise several layers if the benefit phase has more than one component that can separate into phases of liquid and waxy layers, or if there is more than one beneficial component. If the benefit phase splits, the sum of the measured benefit layers is the height of the benefit layer, Hb,. In general, a hydrophobic benefit layer, when present, is on top of the centrifuge tube.
[00134] The surfactant phase can comprise several layers or a single layer, Hc. There may also be an unstructured, isotropic, colorless micellar layer at the bottom or near the bottom of the ultracentrifuge tube. The layers immediately above the isotropic phase generally comprise a higher concentration of surfactants with more ordered structures (such as liquid crystals). These structured layers are sometimes either opaque, or translucent, or clear to the naked eye. Several structured layers can be present, in which case, Hc is the sum of the individual structured layers. If any type of polymer-surfactant phase is present, it is considered a structured phase and included in the measurement of Hc. The sum of the aqueous phases is Hs. [00135] Finally, the volume ratio of the structured domain is calculated as follows:
[00136] Structured Domain Volume Ratio = Hc / Hs * 100% [00137] If there is no benefit phase present, the total height should be used as the height of the surfactant layer, Hs = Ha. For the present invention, the Ratio between structured domain volumes is the percentage of lamellar phase. The measurement is made for each dilution prepared and centrifuged, that is, the ratio between structured domain volumes is determined for the composition, and for
Petition 870180007766, of 01/29/2018, p. 46/88
42/77 dilutions at 90%, 80%, 70% and 60% prepared as indicated above.
[00138] The highest amount of dilution (ie, the lowest dilution level) at which the composition maintains at least 95% of the percentage of lamellar phase is an indicator of the amount of structure for compositions having different values of n for STnS.
[00139] In one embodiment, the highest dilution in which the composition has at least 95% of the lamellar phase is greater than about 15%, alternatively greater than about 25%, alternatively greater than about 35%.
[00140] In one embodiment, the composition has a structured domain volume ratio of at least about 40%, alternatively at least about 45%, alternatively at least about 50%, alternatively at least about 55%, alternatively at least about 60%, alternatively at least about 65%, alternatively at least about 70%, alternatively at least about 75%, alternatively at least about 80%, alternatively at least about 85% and, alternatively, at least about 90% by volume of the aqueous surfactant composition.
[00141] Ultracentrifugation dilution method [00142] The ultracentrifugation dilution method is a physical method used to determine the amount of structure in a composition at a certain point in its dilution profile, which refers to the composition's ability to foam. The Ultracentrifugation Dilution Method uses the results of the Ultracentrifugation Method at the 50% dilution point. When consumers use surfactant compositions with an implement such as a bath loofah or a Puff, about 10 ml of composition is typically dosed on the implement, which can contain about 10 ml of water in it. Consumers stir to foam, requiring the composition to
Petition 870180007766, of 01/29/2018, p. 47/88
43/77 quickly dissolves in this dilution force. The ability of structured surfactant compositions to dissolve at 50% dilution is measured by the method.
[00143] The method is identical, in all its details, to the ultracentrifugation method. The result at 50% dilution is obtained for a composition and is expressed as Lamellar phase volume in 50% dilution.
[00144] The results obtained in the Ultracentrifugation Dilution Method are parallel to the results obtained for the Dissolution Rate Test for the compositions of the present invention comprising STnS, which reaffirms the relationship between high structure and reduced foaming, and vice versa, leading to improved stability and aesthetics of use within a narrower range of values from n to STnS. The ST0S composition of Example 4, being relatively unstructured, has a low structure after dilution, but is unsuitable for the purposes of a structured surfactant composition due to its inability to provide the stabilization indispensable to a composition based on its rheology. The ST3S composition of Example 1 has sufficient structure and rapidly dilutes in micellar surfactants useful for foaming and cleaning, but, disadvantageously, these ST3S compositions cannot be readily formulated into compositions comprising reduced levels of surfactant, and will always remain expensive, inefficient, environmentally less preferred, and less smooth. The ST1S composition of Example 3 has 100% Lamellar Phase Volume in 50% dilution, which will result in unsatisfactory foaming and cleaning characteristics in many modes of use. The ST2S composition of Example 2 demonstrates versatility in that it has a high degree of structure and yet is diluted enough to provide a good result in terms of foaming, the performance of the foam being supported by its value of 70% for Phase Volume
Petition 870180007766, of 01/29/2018, p. 48/88
44/77 lamellar in 50% dilution. ST2S compositions can be prepared with reduced levels of surfactant, for example to 15%, or 12%, or 10% or 8% or even 6% of surfactant, and retain many of the preferred features of the present invention.
[00145] In one embodiment of the present invention, the volume of the lamellar phase in 50% dilution for a composition of the present invention is less than about 90%, alternatively less than about 80% and, alternatively, less than 75%.
[00146] Dissolution rate method [00147] Structured compositions are prone to slow dissolution, which can result in unsatisfactory foaming and cleaning characteristics. The slowly dissolving structured surfactant phases have largely been behind the development of the Puff implement for many years, and a shaking implement that encourages dissolution, foaming and cleaning. Foaming and cleaning result from the ability of aqueous surfactant molecules to diffuse and stabilize interfaces with air and dirt surfaces. When surfactants remain trapped in lamellar structures or other organized structures, they are unable to diffuse into the aqueous phase and, therefore, must first dissolve as individual surfactant monomers and micelles to be effective. Dilution and agitation encourage dissolution during use. The Dissolution Rate Method measures the extent of dissolution of a surfactant composition in water.
[00148] A glass beaker with straight walls having an internal diameter (d.i.) of 63 mm and an internal height of 87 mm is obtained, for example Pyrex 250 mL (n ° 1000), which is widely available. 150 grams of distilled water at room temperature (24 ° C (75 ° F) are poured into the beaker. A magnetic stir bar coated with
Petition 870180007766, of 01/29/2018, p. 49/88
45/77
Teflon® is added to the beaker. The stir bar is nominally 3.81 cm long x 0.79 cm in diameter (1.5 inches long x 5/16 inches in diameter), having an octagonal shape when viewed from the end, and a pivot ring molded 0.16 cm (1/16 inch) around its center, where the diameter is increased to about 0.89 cm (0.35 inch). Spinbar® magnetic stir bars are available from Sigma Aldrich Corp. worldwide, including Milwaukee, WI, USA, and www.sigmaaldrich.com.
[00149] Measure and note the initial water conductivity using a conductometer, for example, a MettlerToledo SevenMulti meter with InLab740 probe, and note the value. The conductivity of the water needs to be about microSiemens / cm (uS / cm) or less to indicate the presence of a low content of dissolved solids. Remove the conductivity probe from the water and place the beaker on a digitally controlled laboratory stirrer, for example an Ika ® Werke RET Control-visc, available for example from DivTech Equipment Co, Cincinnati, OH, USA. The beaker is centered on the agitator which, in turn, is activated to obtain a constant rotation speed of 500 rpm, establishing a vortex in the water that measures about cm deep from the highest point of the water at the beaker's edge. and to the lowest point in the air at the center of the vortex. Observe the top vortex to ensure that it is centered in the beaker, and that the magnetic stir bar is centered in the center of the vortex.
[00150] Obtain a cleaning phase and fill with a 1 mL syringe, without capturing air. The syringe has a diameter of about 1.9 mm at the tip (for example, a 1 mL BD slip-type tuberculin model from Becton, Dickinson and Co., Franklin Lakes, NJ, USA). Inject the cleaning phase in a constant current over the upper surface of the water, near the edge of the beaker however
Petition 870180007766, of 01/29/2018, p. 50/88
46/77 without touching it. The composition needs to be injected in about 1 second. Start a timer and allow the composition to stir for 30 seconds.
[00151] Turn off the stirrer. Insert the conductivity probe into the water, in a location away from any undissolved solids. Allow the measurement to stabilize, take a conductivity reading, and note the Conductivity.
[00152] Reconnect the stirrer. Restart the timer when the digital reading exceeds 250 rpm. After an additional 30 seconds, switch off the stirrer and measure the conductivity in the same way as previously performed. Note the conductivity.
[00153] Reconnect the stirrer. Restart the timer when the digital reading exceeds 250 rpm. After an additional 60 seconds, switch off the stirrer and measure the conductivity in the same way as previously performed. Note the conductivity.
[00154] Remove the probe from the water without disturbing any remaining solids. Cap the beaker with a suitable waterproof cap, for example with a plastic wrap and a rubber strip. Shake the beaker vigorously for about 30 seconds to dissolve the remaining solids, using a vortex mixer in addition, if necessary.
[00155] Uncap the beaker, measure the conductivity and note the value as Final Conductivity.
[00156] The percentage of dissolution at each point in time is calculated according to the following equation:
Dissolution percentage = 100% x (Conductivity Initial water conductivity) (Final conductivity Initial water conductivity)
Petition 870180007766, of 01/29/2018, p. 51/88
47/77
At the present point used for [00157] Repeat the measurement as necessary, to obtain a representative average value.
[00158] The dissolution test data for STnS compositions is illustrated in figure 1.
[00159] At the 60 second time point, the compositions of the present invention have a dissolution percentage of at least about 60%, alternatively at least about 70% or, alternatively, at least about 80% in time at 120 seconds, the compositions of the invention have a dissolution percentage of at least about 80%, alternatively at least about 85%, alternatively at least about 90% or, alternatively, at least about 95%.
[00160] Third-phase method for determining the stability of the structured surfactant:
[00161] The third phase method is to determine the stability of the structured surfactant phase in a personal hygiene composition. The method involves placing the personal care compositions at 50 ° C for 10 days for rapid aging. After rapid aging, transfer about 4 grams of the composition into a Beckman centrifuge tube (11 x 60 mm). Place the centrifuge tube in a Beckman LE-80 ultracentrifuge and operate the ultracentrifuge under the following conditions: 50,000 rpm, 2 hours and @ 40 ° C. [00162] After ultracentrifugation, determine the volume of the third phase by measuring the height of several surfactant phases, using a digital electronic gauge (accurate to 0.01 mm) as shown in figure 10. In figure 10 an example of a personal hygiene composition comprising Expancel microspheres is shown. [00163] The topmost layer is the hydrophobic benefit phase layer (hydrocarbons or soy oil etc.). The layers below the hydrophobic benefit phase layers contain surfactant / water, and are determined
Petition 870180007766, of 01/29/2018, p. 52/88
48/77 as shown below: Ha is the height of all layers containing surfactant / water, and Hb is the height of the colorless layer of the third phase, just below the layer of the hydrophobic benefit phase. It is important to note the readings within 30 min after the ultracentrifugation is finished, to minimize material migration between different layers. The volume of the third phase is calculated as:% of the volume of the third phase = Hb / Ha * 100% [00164] Preferably, the structured surfactant composition comprises less than 10% by volume of the third phase, after the stability protocol with rapid aging. More preferably, the structured surfactant composition comprises less than 5% by volume of the third phase, after the fast aging stability protocol. More preferably, the structured surfactant composition comprises less than 2% by volume of the third phase, after the fast aging stability protocol. Even more preferably, the structured surfactant composition comprises less than 1% by volume of the third phase, after the rapid aging protocol. With the utmost preference, the structured surfactant composition comprises about 0% by volume of the third phase, after the rapid aging protocol.
[00165] EXAMPLES [00166] The following examples describe modalities within the scope of the invention. The examples are provided for illustrative purposes only and should not be considered as limitations to the present invention, since many variations of it are possible, without deviating from the character and scope of the invention.
[00167] Comparisons with the STnS composition demonstrate [00168] The prepared mix.
compositions by the addition of
Table I (below) were water in a container of
Then, add the following ingredients under
Petition 870180007766, of 01/29/2018, p. 53/88
49/77 continuous mixing: sodium chloride, sodium lauro anfoacetato de sodium, sodium tridecet sulfate, sodium tridecyl sulfate, tridecet-3, EDTA and sodium benzoate. Adjust the pH by adding citric acid solution (50% active) under pH = 5.7 ± 0.2. Then, add methyl chloro isothiazolinone and methyl isothiazolinone. Continue mixing until homogeneity is achieved.
[00169] After preparing these compositions, the volume of the lamellar phase, the Young's Modulus and the Viscosity were determined under a zero shear rate, using the methods presented here. The results are captured below in Table I, as well as graphically in figures 2 and 3. Figure 2 shows the viscosity profile as a function of the shear stress of the inventive and comparative examples. It is shown that the viscosity profile of Inventive Example 2 (identified as sodium tridecet-2 sulfate) is significantly higher than that of Comparative Example 4 (identified as sodium tridecet1 sulfate) and Comparative Example 3 (identified as tridecyl sulfate) sodium), being also higher than that of Comparative Example 1 (identified as sodium tridecet-3 sulfate). Figure 3 graphically represents Young's Modulus for the examples in Table I.
Table I
Phase compositionsurfactant Examplecomparative 1(% Weight/Weight) Example2(% Weight/Weight) Example3(% Weight/Weight) Examplecomparative 4(% Weight/Weight) Tridecet-3 sodium sulfate ¹ 16, 56 - - - Tridecet-2 sodium sulfate ¹ - 16, 56 - - Tridecet-1 sodium sulfate ¹ - - 16, 56 - Sodium tridecyl sulfate ¹ - - - 16, 56 Sodium Lauryl Sulfate ²
Petition 870180007766, of 01/29/2018, p. 54/88
50/77
Lauro sodium anfoacetate ³ 4.94 4.94 4.94 4.94 Tridecet-3 (BHL = 8) ⁴ 2.0 2.0 2.0 2.0 Sodium chloride 4.75 4.75 4.75 4.75 Methyl chlorine isothiazolinone and methyl isothiazolinone ⁵ 0.033 0.033 0.033 0.033 EDTA ⁶ 0.15 0.15 0.15 0.15 Sodium benzoate 0.2 0.2 0.2 0.2 Citric acid, solution abe titrated (pH = ± 0.2) 5.7 5.7 5.7 5.7 Water q.s. q. ^s . q. ^s . q. ^s . Total surfactant of 21.5% 21.5% 21.5% 21.5% foaming at the stage cleaning (%) Lamellar phase volume (%) 100% 100% 100% 0% Young's Modulus (Pa) 100, 0 131.6 38.57 0.26 Viscosity underzero shear (PaS) 2 552 3 · 060 1 029 10.7
2
- ¹ · available from Stepan Coporation ² · available from Procter & Gamble Co ·, ³ · available from Cognis Chemical Corp · ⁴ · Iconal TDA-3 available from BASF Corp · ⁵ · Kathon CG, available from Rohm & Haas Company, Philadephia, PA, USA, ⁶ · Dissolvine NA 2x · [00170] Dilution test for examples 1 to 4 [00171] The compositions in Table I were tested by dilution in deionized water · Samples with dilution factors 10% samples were prepared by adding 10 grams of deionized samples to comparative samples and with gram factors of the inventive compositions, mentioned above. The dilutions of 20% to 60% were prepared by adding 20 to 60 grams of deionized water. to 80 to 40 grams of the above mentioned comparative and inventive compositions · These samples were mixed well using a SpeedMixer ™ (model
Petition 870180007766, of 01/29/2018, p. 55/88
51/77
DAC, 400FV, available from FleckTeck, Inc, USA) at 2,000 rpm for 60 seconds. The volume of the lamellar phase is determined by the Ultracentrifugation Method, as described in the Methods section. The results for this test were captured in Table II, and graphically represented in figures 4 and 5. Figure 4 illustrates the highest dilution maintaining a lamellar volume of 100%. Figure 5 illustrates the percentage of lamellar phase as the dilution increases. In inventive Example 2, the ST2S formulation surprisingly maintained a volume of the lamellar phase from 100% to a dilution of 40%. The volume of the lamellar phase of Comparative Example 1 (ST3S) started to decrease much earlier.
Table II
Dilution factor in water 10% 20% 30% 40% 50% 60% deionized Total surfactant component 19.35% 17.2% 15.05% 12.9% 10.75% 8.6% foaming process in the cleaning (%) Lamellar phase volume (%) ofComparative Example 1 under dilution 100% 92.07% 47.44% 25.77% 21.84% 7.27% Lamellar phase volume (%) ofExample 2 under dilution 100% 100% 100% 100% 69.88% 32.58% Lamellar phase volume (%) ofExample 3 under dilution 100% 100% 100% 100% 100% 100% Lamellar phase volume (%) ofComparative Example 4 under dilution 0% 0% 0% 0% 0% 0% [00172] Lipid stability and c .performance c the foam
[00173] The compositions in Table I were combined with a second lipid phase, the composition of which is illustrated in Table III (a), to form a two-phase composition. The lipid phase was prepared by heating the petrolatum and mineral oil to about 88 ° C, and they were then mixed together. Cool the lipid phase with stirring to 45 ° C. Cease agitation and cool
Petition 870180007766, of 01/29/2018, p. 56/88
52/77 the lipid phase overnight, until the ambient condition. The surfactant and the lipid phase are combined using a SpeedMixer ™ (model DAC, 400FV, available from FleckTeck, Inc, USA) at 800 rpm for 60 seconds. After the formation of these multi-phase compositions, stability tests and subsequent tests are carried out. Stability is assessed after aging the products at 50 ° C for 10 days. Inventive Example 3 maintained 100% of the lamellar phase, while Comparative Examples 1 and 2 showed a volume of the lamellar phase decreased from 100% to about 86% and 77%, respectively. The foam performance of the product was assessed with a Puff implement. Ten grams of test product are added over a pouf in a circular motion. Add 10 grams of water. Rub the products on the Puff. Then, hold the Puff over a beaker to collect the foam. Rotate and squeeze the Puff 10 times, then 10 times in the opposite direction, at a speed of one squeeze per second. At the end of the rotation, pull the rope three times to squeeze the Puff. Flatten the foam in the beaker and take the volume measurement. The foam volume is classified on the scale as shown below:
Observed foam volume range Classification
Volume in foam <1. 000 mL 1 - unsatisfactory 1,000 mL < Volume in foam <1,500 mL 2 - regular 1,500 mL < Volume in foam <2,000 mL 3 - Good 2,000 mL < Volume in foam <2,500 mL 4 - Very good Volume in foam > 2. 500 mL 5 - Great
[00174] Inventive Example 3 (sodium tridecet-2 sulfate) showed a significantly higher foam volume (2,600 ml) than that of Comparative Example 4 (sodium tridecet-1 sulfate, 1,500 ml). The trend in the volume of foam observed is consistent with the profile of
Petition 870180007766, of 01/29/2018, p. 57/88
53/77 dilution shown in figure 2. The compositions of Comparative Example 4 (sodium tridecet-1 sulfate) maintained the lamellar phase even under a high dilution factor (dilution factor up to 60%) and are therefore slower in foam generation, while Inventive Example 3 showed excellent lamellar phase stability after 10 days @ 50 ° C and high foam performance, due to the excellent phase transition at a dilution factor of about 40% (figure 2) .
Table III (a)
Composition of the lipid phase(% weight / weight) Petrolato 70, 0 Mineral oil 30, 0
Table III (b)
Examplecomparative 1+ Lipid@ 55: 45weight / weight Exampleinventive 2+ Lipid@ 55: 45weight / weight Examplecomparative 3+ Lipid@ 55: 45weight / weight Examplecomparative 4+ Lipid@ 55: 45weight / weight Initial volume oflamellar phase 100% 100% 100% 0% Phase volumelamellate after10 days @ 50 ° C 77% 100% 100% 0%(it is notstable) Foam volume 4 5 2 5 observed with thePuff implement Very good Great Regular Great
[00175] Comparative compositions with cotensoatives [00176] Prepared mixtures. mixing compositions by adding
Table IV (below) were water in a cocamidopropyl container
Then, add the following ingredients under continuous: sodium chloride, cocobetaine, betaine, lauroamidopropyl betaine,
Petition 870180007766, of 01/29/2018, p. 58/88
54/77 decyl glycoside, sodium cocoyl glycinate, sodium tridecet-2 sulfate, tridecet-3, EDTA and sodium benzoate. Adjust the pH by adding citric acid solution (50% active) under pH = 5.7 ± 0.2. Then, add methyl chloro isothiazolinone and methyl isothiazolinone. Continue mixing until homogeneity is achieved.
[00177] After preparing these compositions, the volume of the lamellar phase, the Young's Modulus and the Viscosity were determined under a zero shear rate, using the methods presented here. The results are shown below, in Table IV. Both the comparative examples and the inventive examples have high volumes of lamellar phase (70% to 100%), and high values for Young's modulus (from about 95 Pa to about 249 Pa) and viscosity under zero shear rate (from about 2,544 PaS to about 5,757 PaS).
Table IV
Phase compositionsurfactant Example5(% Weight/Weight) Example6(% Weight/Weight) Example7(% Weight/Weight) ExampleComparative 8(% Weight/Weight) ExampleComparative 9(% Weight/Weight) Tridecet-2 sulfatesodium 16, 56 16, 56 16, 56 16, 56 16, 56 Cocobetaine 4.94 Cocoamidopropyl betaine 4.94 Lauro starchpropylbetaine 4.94 Decyl glycoside 4.94 Cocoyl glycinatesodium 4.94 Tridecet-3 (BHL = 8) 2.0 2.0 2.0 2.0 2.0 Sodium chloride 4.75 4.75 4.75 4.75 4.75 Methyl chlorineisothiazolinone and methyl 0.033 0.033 0.033 0.033 0.033
Petition 870180007766, of 01/29/2018, p. 59/88
55/77
isothiazolinone EDTA 0.15 0.15 0.15 0.15 0.15 Sodium benzoate 0.2 0.2 0.2 0.2 0.2 Citric acid, solutionto be titled(pH = ± 0.2) 5.7 5.7 5.7 5.7 5.7 Water q.s. q. ^s . q. ^s . q. ^s . q. ^s . Component Total 21.5% 21.5% 21.5% 21.5% 21.5% formation surfactant foam in the cleaning (%) Phase volumelamellar (%) 100% 100% 100% 70% 100% Young's Modulus (Pa) 95, 1 248.9 134.2 185.5 176.6 Viscosity underzero shear (PaS) 2,544 5,757 3,507 4,809 3,836
[00178] Dilution test for examples 5 to 9 [00179] The compositions in Table IV (a) were tested by dilution in deionized water based on the same procedure described in detail in the dilution test for Examples 1 to 5. The results for this test were captured in Table V, and are graphically represented in figure 6. Figure 6 also contains the dilution profile of Inventive Example 3 (lauro anfoacetato de sodium). Inventive Examples 5 to 7 of the ST2S formulation surprisingly maintained a high volume of the lamellar phase until a dilution of 30% to 50%. The volume of the lamellar phase of Comparative Examples 8 and 9 begins to decrease much earlier (at a dilution factor less than 20%).
Table V
Dilution factor in water 10% 20% 30% 40% 50% 60%
Petition 870180007766, of 01/29/2018, p. 60/88
56/77
deionized Total surfactant component 19.35% 17.2% 15.05% 12.9% 10.75% 8.6% foaming phase cleaning (%) Lamellar phase volume (%) ofExample 5 under dilution 100% 100% 100% 100% 100% 37.7% Lamellar phase volume (%) ofExample 6 under dilution 100% 100% 100% 58.6% 42.4% 18.3% Lamellar phase volume (%) ofExample 7 under dilution 100% 100% 100% 74.6% 34.4% 18.3% Lamellar phase volume (%) ofExample 8 under dilution 61% 0% 0% 0% 0% 0% Lamellar phase volume (%) ofExample 9 under dilution 100% 0% 0% 0% 0% 0%
[00180] Lipid stability and foam performance [00181] The compositions in Table IV were combined with a second lipid phase, the composition of which is illustrated in Table III (a), to form a multi-phase composition. The surfactant and the lipid phase are combined using a SpeedMixer ™ (model DAC, 400FV, available from FleckTeck, Inc, USA) at 800 rpm for 60 seconds. After the formation of these multi-phase compositions, stability tests and subsequent tests are carried out. Stability is assessed by measuring the volume of the lamellar phase using the ultracentrifugation method, after aging the products at 50 ° C for 10 days. Inventive Examples 5 to 7 maintained 100% of the lamellar phase, while Comparative Examples 8 to 9 showed a volume of the lamellar phase decreased from 100% to about 0%. The stability profile of the lamellar phase shows a surprisingly similar trend, as shown in figure 7, which showed that Comparative Examples 8 to 9 had a significant decrease in phase volume
Petition 870180007766, of 01/29/2018, p. 61/88
57/77 lamellar under lower dilution factors, while Inventive Examples 2 and 5 to 7 showed phase transition points to higher dilution factors.
Table VI
Example 5+ Lipid@ 55: 45weight / weight Example 6+ Lipid@ 55: 45weight / weight Example 7+ Lipid@ 55: 45weight / weight ExampleComparative8+ Lipid@ 55: 45weight / weight ExampleComparative9+ Lipid@ 55: 45weight / weight Initial volume oflamellar phase 100% 100% 100% 69.7% 100% Lamellar phase volumeafter stability -10 days @ 50 ° C 100% 100% 100% 0%(it is notstable) 0%(it is notstable)
[00182] Compositions_comparatives_with_ associative polymers [00183] Examples 10 to 16 illustrate the effectiveness of the associative polymers of the present invention. The compositions in Table VI (below) were prepared first by adding water to a mixing vessel. Then, add the following ingredients under continuous mixing: sodium chloride, hydroxy propyl chloride trimonium guar, sodium lauro anfoacetate, sodium tridecet-2 sulfate. Then, add the polymer powders (Aqupec and Stabylen 30 polymers) in tridecet-3, to form a premix. Add the polymer-tridecet-3 premix to the main mixer tank, under appropriate stirring. Aqua SF-1 is an aqueous dispersion, and is added directly to the mixing vessel without pre-mixing with tridecet-3. Then, add EDTA and sodium benzoate. Adjust the pH by adding citric acid solution (50% active) under pH = 5.7 ± 0.2. Then, add methyl chloro isothiazolinone and methyl isothiazolinone. Continue mixing until homogeneity is achieved. The multiphase composition is
Petition 870180007766, of 01/29/2018, p. 62/88
58/77 prepared by adding soybean oil to the surfactant phase composition using a SpeedMixer ™, at a speed of 2,000 rpm for 60 seconds.
[00184] After preparing these compositions, the volume of the lamellar phase, the Young's Modulus and the Viscosity were determined under a zero shear rate, using the methods presented here. The results were captured below, in Table VII. Inventive Examples 11 through 14 showed a significant increase in Young's modulus from about 145% to about 388%, while Comparative Examples 15 and 16 showed an effect between minimal and negative to the structure of the composition. The magnitude of the increase in Young's modulus is surprising due to the low content of use (about 0.2%). It is believed that the synergistic behavior is attributed to the strong association interaction between the hydrophobic polymer chain and the lamellar vesicles of the surfactant composition.
Petition 870180007766, of 01/29/2018, p. 63/88
59/77
Table VII
Composition ExampleComparative 10(% Weight/Weight) Example11(% Weight/Weight) Example12(% Weight/Weight) Example13(% Weight/Weight) Example14(% Weight/Weight) ExampleComparative 15(% Weight/Weight) ExampleComparative 16(% Weight/Weight) Tridecet-2 sodium sulfate 7.30 7.30 7.30 7.30 7.30 7.30 7.30 Lauro sodium anfoacetate 2.18 2.18 2.18 2.18 2.18 2.18 2.18 Tridecet-3 (BHL = 8) 0.88 0.88 0.88 0.88 0.88 0.88 0.88 Sodium chloride 4.28 4.28 4.28 4.28 4.28 4.28 4.28 Hydropropyltrimony chlorideguar gum 0.38 0.38 0.38 0.38 0.38 0.38 0.38 Acrylate cross polymer / C10-C30 alkyl acrylates(Aqupec SER-300) 0.18 Acrylate cross polymer / C10-C30 alkyl acrylates(Aqupec SER-150) 0.18 Acrylate cross polymer / C10-C30 alkyl acrylates 0.18 (Aqupec HV-701EDR) Cross polymeracrylates / vinyl isodecanoate 0.18
Petition 870180007766, of 01/29/2018, p. 64/88
60/77
(Stabylen 30) Carbomer(Aqupec HV504E) 0.18 Acrylate copolymer(Aqu SF-1) 0.18 Methyl chlorine isothiazolinone and methyl isothiazolinone ⁵ 0.03 0.03 0.03 0.03 0.03 0.03 0.03 EDTA ⁶ 0.14 0.14 0.14 0.14 0.14 0.14 0.14 Sodium benzoate 0.18 0.18 0.18 0.18 0.18 0.18 0.18 Citric acid, solution to betitled(pH = ± 0.2) 5.7 5.7 5.7 5.7 5.7 5.7 5.7 Soy oil 10 10 10 10 10 10 10 Water q.s. q. ^s . q. ^s . q. ^s . q. ^s . q. ^s . q. ^s . Total surfactant component of 9.48% 9.48% 9.48% 9.48% 9.48% 9.48% 9.48% foaming in the composition Lamellar phase volume (%) 93% 96.4% 100% 100% 100% 87% 100% Young's Modulus (Pa) 19.04 93.04 76, 67 52.43 46, 77 19.57 6, 6 Percentage of module increaseYoung versus control without 388% 303% 175% 145% 3% -65%
Petition 870180007766, of 01/29/2018, p. 65/88
61/77
polymer Volume of foam in the cylinder (mL) 530 505 480 482 495 545 520
Petition 870180007766, of 01/29/2018, p. 66/88
62/77 [00185] Comparative compositions with cationic deposition polymers [00186] The compositions in Table VIII (below) were prepared by adding water in a mixing vessel. Then, add the following ingredients under continuous mixing: sodium chloride, hydroxy chloride propyl trimonium guar, sodium anfoacetate sodium, sodium tridecet sulfate, tridecet-3, EDTA and sodium benzoate. Adjust the pH by adding citric acid solution (50% active) under pH = 5.7 ± 0.2. Then, add methyl chloro isothiazolinone and methyl isothiazolinone. Continue mixing until homogeneity is achieved. The benefit phase was prepared by heating petrolatum and glyceryl monooleate to about 85 ° C. Then, mix the petrolatum and the glyceryl monooleate together, under mixing. Cool the lipid phase to 45 ° C under slow stirring. Stop stirring and cool the lipid phase overnight to room temperature. Add TiO ₂ to the lipid, using a SpeedMixer ™ at 2,000 rpm for 60 seconds. Deposition was assessed using an in-vitro deposition method (Delta-L). The data showed that the charge density of the cationic polymer is of critical importance for deposition. When the cationic charge density is too low (less than 0.8 meq / g) or too high (greater than 2.0 meq / g), deposition is significantly reduced. The optimum charge density for obtaining high deposition is between about 0.8 meq / g and about 2.0 meq / g.
Table VIII
Comp.Example17 Comp.Example18 Example19 Example20 Example21 I: Surfactant phase composition Tridecet-2 sodium sulfate 11.59 11.59 11.59 11.59 11.59 Lauro sodium anfoacetate 3.46 3.46 3.46 3.46 3.46
Petition 870180007766, of 01/29/2018, p. 67/88
63/77
Tridecet-3 (BHL = 8) 1.40 1.40 1.40 1.40 1.40 Sodium chloride 4.75 4.75 4.75 4.75 4.75 Hydropropyltrimony chlorideguar gum(charge density = 0.18 meq / g) 0.60 Hydropropyltrimony chlorideguar gum(charge density = 0.72 meq / g) 0.60 Hydropropyltrimony chlorideguar gum(charge density = 0.95 meq / g) 0.60 Hydropropyltrimony chlorideguar gum(charge density = 1.60 meq / g) 0.60 Hydropropyltrimony chlorideguar gum(charge density = 2.45 meq / g) 0.60 (pH = ± 0.2, citric acid or NaOH) (5.7) (5.7) (5.7) (5.7) (5.7) EDTA 0.15 0.15 0.15 0.15 0.15 Sodium benzoate 0.2 0.2 0.2 0.2 0.2 Methyl chlorine isothiazolinone and methylisothiazolinone 0.033 0.033 0.033 0.033 0.033 Water q- ^s · q- ^s · q- ^s · q- ^s · q- ^s · II: Composition of the benefit phase Petrolato 91.47 91.47 91.47 91.47 91.47 Glyceryl monooleate 1.87 1.87 1.87 1.87 1.87 Titanium oxide (RBTD-834-11S2,available from Kobo Products) 6.66 6.66 6.66 6.66 6.66 III: Ratio between thesurfactant and the benefit phase(weight / weight) 85:15 85:15 85:15 85:15 85:15 In-vitro deposition (Delta L) 0.36 7.65 16, 96 18.70 8.75
Petition 870180007766, of 01/29/2018, p. 68/88
64/77 [00187] Additional exemplary formulations [00188] The additional exemplary formulations mentioned below, in Table IX.
are
Petition 870180007766, of 01/29/2018, p. 69/88
65/77
Table IX
Compositions Example 22(% Weight/Weight) Example 23(% Weight/Weight) Example 24(% Weight/Weight) Example 25(% Weight/Weight) Example 26(% Weight/Weight) Example 27(% Weight/Weight) Example 28(% Weight/Weight) Example 29(% Weight/Weight) Tridecet-2 sodium sulfate 7.30 7.30 7.30 6.89 10.3 6, 5 6, 5 7.30 Lauro sodium anfoacetate 2.18 2.18 2.18 2.05 - 1.9 1.9 Cocamido Propyl Betaine - - - - 3.18 - - 2.18 Tridecet-3 0.88 0.88 0.88 0.83 1.24 0.78 0.78 0.88 Guar hydroxy chloridepropyl triamonium(N-Hance 3196, CD = 0.7 meq / g) 0.53 Guar hydroxy chloridepropyl triamonium(N-Hance CG-17, CD = 0.9 meq / g) 0.38 0.38 0.38 0.36 0.34 0.34 0.38 Cross polymeracrylates / alkyl acrylatesC10-C30 (Aqupec SER 300) 0.18 0.18 0.18 0.17 0.16 0.16 0.18 PEG-90M - - - - 0.13 - - Sodium chloride 4.28 4.28 4.28 4.04 4.22 4.5 4.5 4.28 Citric acid / hydroxidesodium pH = 5.7 pH = 5.7 pH = 5.7 pH = 5.7 pH = 5.7 pH = 5.7 pH = 5.7 pH = 5.7 Petrolato 9.80 - 1.96 - - - - -
Petition 870180007766, of 01/29/2018, p. 70/88
66/77
Glyceryl monooleate 0.20 - 0.04 - - - - - Soy oil - 10.0 8 15.0 10 - 5.0 10.0 Dimethicone - - - - - 5.0 - Water / preservatives / perfume q. ^s . q. ^s . q. ^s . q. ^s . q. ^s . q. ^s . q. ^s . q. ^s . Lamellar phase percentage Young's Modulus (Pa) 114.2 47.6 33.7 18.4 36.0 28.4 33.5 43.7
Petition 870180007766, of 01/29/2018, p. 71/88
67/77 [00189] Clinical study: evaluation of the skin's hydration benefit [00190] The clinical study design consisted of a controlled application test leg protocol (TACP) for liquid body soap, used to evaluate the effects benefits of personal care products on dry leg skin. Studies on leg washing are designed to approximate exposure levels relevant to the consumer, for example the frequency of washing. The technique used in this study is a modification of a published procedure (Ertel, et al, 1999). References: Ertel, K.D., Neumann, P. B., Hartwig, P. M., Rains, G. Y., and Keswick, B.
H., Leg Wash protocol to assess the skin moisturization potential of personal cleansing products, Int. J. Cosmet. Sci. 21: 383-397 (1999).
[00191] Clinical test design: Human patients were screened for a score of 2.0 or more for dry skin, according to the dryness classification procedure described below.
Grade ^to Dryness ¹¹
0.0 perfect skin
1.0 areas of raster and / or slight dust formation, occasionally areas with small scales can be seen, widespread distribution
2.0
3.0
4.0
5.0
6, 0 slight formation of generalized dust, early formation of cracks or occasional lifting of small scales may be present moderate formation of generalized dust and / or moderate formation of cracks and scales strong formation of generalized dust and / or strong formation of cracks and lifting scales high crack formation and generalized scales lifting, eczematous alteration may be present, but not prominent, cracks with bleeding can be seen severe generalized cracks, bleeding cracks and eczematous alterations may be present, large
Petition 870180007766, of 01/29/2018, p. 72/88
68/77 scales may be loosening ^to half-unit degrees can be used, if necessary ^b 'generalized' refers to situations where more than 50% of the application area is affected [00192] A cohort of 38 individuals was selected for each treatment. All individuals were preconditioned with Olay® soap bars for 7 days, followed by 1 application / day, for 3 weeks, and regression for 2 days. The measurements included grading the dry skin, corneometer, PTEA, cutometer and pieces of tape to obtain biomarker analytes. The treatment design is shown in Table X, below. Code A was an untreated control (water only). Code B was a commercially available liquid body soap Olay Crème Ribbons, purchased from Walmart for use as a Comparative Example, which contains about 25% petrolatum / mineral oil as a benefit phase. The formulations for code C, D, E and F are provided in Tables XI, below. The results of clinical tests for dryness are provided in Tables XII to XV.
[00193] Table X: TACP-1 clinical test design TACP-1 clinical test design [A] Water (no treatment) (comparative) [B] Olay Crème Ribbons (comparative, 25% lipid phase) [C] Inventive example 30 [D] Inventive example 31 [E] Inventive example 32 [F] Inventive example 33 [00194] Table XI
Compositions Example30 Example31 Example32 Example33 Tridecet-2 sodium sulfate 6, 89 7.30 6, 89 6, 89
Petition 870180007766, of 01/29/2018, p. 73/88
69/77
Lauro sodium anfoacetate 2.05 2.18 2.05 - Cocamido Propyl Betaine - - - 2.05 Tridecet-3 0.83 0.88 0.83 0.83 Guar hydroxy propyl chloridetriamonium(N-Hance CG-17, CD = 0.9 meq / g) 0.36 0.38 0.36 0.36 Cross polymeracrylates / alkyl acrylatesC10-C30 (Aqupec SER 300) 0.17 0.18 0.17 0.17 Sodium chloride 4, 04 4.28 4, 04 4, 04 Citric acid / sodium hydroxide pH = 5.7 pH = 5.7 pH = 5.7 pH = 5.7 Petrolato 14.7 9, 80 - 14.7 Glyceryl monooleate 0.3 0.20 - 0.3 Soy oil - - 15, 0 - Water / preservatives / perfume q- ^s · q- ^s · q- ^s · q- ^s · Total surfactant for the formation offoam 8, 89 9.48 8, 94 8, 94 Percentage of phase volumelamellate Young's Modulus (Pa) Viscosity underzero shear (PaS)
[00195] Table XII: Results of visual dryness assessment
Attribute Evaluation Size ofsample Treatment Grouping * Averageadjusted Mistake-standard Degrees ofdrynessevaluatedby expert Base 37 [F] Example 33 The 2,669 0.069 38 [E] Example 32 ab 2,718 0.069
Petition 870180007766, of 01/29/2018, p. 74/88
70/77
38 [The water(nonetreatment) ab 2,749 0.069 36 [B] Olay CrèmeRibbons B 2,794 0.070 37 [C] Example 30 B 2.801 0.069 37 [D] Example 31 B 2,824 0.069 Attribute Evaluation Size ofSample Treatment Grouping * Averageadjusted Mistake-standard Degrees ofdrynessevaluatedby expert 3 hoursafter thetreatment1 (1.3) 36 [C] Example 30 The 1,772 0. 118 37 [F] Example 33 The 1,830 0.117 37 [E] Example 32 ab 1,950 0.117 35 [D] Example 31 ab 2,022 0. 120 35 [B] Olay CrèmeRibbons B 2,116 0. 120 36 [The water(nonetreatment) ç 2,774 0. 118 Attribute Evaluation Size ofSample Treatment Grouping * Averageadjusted Mistake-standard Degrees ofdrynessevaluatedby expert 3 hoursafter thetreatment5 (5.3) 35 [C] Example 30 The 0.525 0. 118 36 [F] Example 33 The 0.675 0.117 35 [D] Example 31 B 1.089 0. 118 37 [E] Example 32 B 1,289 0.115 34 [B] Olay CrèmeRibbons B 1.386 0. 120 35 [The water(nonetreatment) ç 2,828 0. 118
Petition 870180007766, of 01/29/2018, p. 75/88
71/77
Attribute Evaluation Size ofSample Treatment Grouping * Averageadjusted Mistake-standard Degrees ofdrynessevaluatedby expert 3 hoursafter thetreatment12 (12.3) 35 [C] Example 30 The 0, 103 0. 085 36 [F] Example 33 ab 0.129 0.084 35 [D] Example 32 B 0.339 0. 085 34 [B] Olay CrèmeRibbons ç 0.753 0.086 37 [E] Example 32 ç 0.927 0.083 35 [The water(nonetreatment) d 2,569 0. 085
[00196] Table XIII: Design of the TACP-2 clinical test with Comparative Example 34 and water.
Clinical trial design TACP-2 [G] No treatment - only water [H] Comparative Example 34
Composition Comparative Example 34 Tridecet-3 sodium sulfate 6.32% Sodium lauryl sulfate 6.30% Lauro sodium anfoacetate 3.74% Sodium chloride 4.00% Tridecet-3 1.48% Fragrance 0.80% Citric acid 0.70% Guar hydroxy propyl triamonium chloride 0.44% Copolymer ofacrylonitrile / methacrylonitrile / methacrylatemethyl, isopentane 0.27%
Petition 870180007766, of 01/29/2018, p. 76/88
72/77
Xanthan gum 0.16% Sodium benzoate 0.15% PEG-90M 0.11% Disodium EDTA 0.11% Methyl chlorine isothiazolinone, Methyl isothiazolinone 0.0004% Glycine soybean oil (soybean) 15.0000% Water q. ^s .
[00197] Table XIV: Results of the visual dryness assessment of Comparative Example 34
Attribute Day Size ofSample Treatment Grouping * SquaresminimumsAverage Mistake-standard Degrees ofdrynessevaluatedby expert Day 1,levelbasal 26 [H] ExampleComparative 34 ab 2,615 0.07 24 [G] Nonetreatment -only water B 2,744 0.080 Attribute Day Size ofSample Treatment Grouping * SquaresminimumsAverage Mistake-standard Degrees ofdrynessevaluatedby expert Day 1,3 hours 26 [H] ExampleComparative 34 The 2,091 0. 120 24 [G] Nonetreatment -only water B 2,523 0.125 Attribute Day Size ofSample Treatment Grouping * SquaresminimumsAverage Mistake-standard
Petition 870180007766, of 01/29/2018, p. 77/88
73/77
Degrees ofdrynessevaluatedby expert Day 5,3 hours 26 [H] ExampleComparative 34 The 2,466 0. 132 24 [G] Nonetreatment -only water The 2,641 0. 138 Attribute Day Size ofSample Treatment Grouping * SquaresminimumsAverage Mistake-standard Degrees ofdrynessevaluatedby expert Day 12,3 hours 24 [H] Nonetreatment -only water The 2,827 0. 163 26 [G] ExampleComparative 34 The 3, 137 0. 156
[00198] Table XV: Design of the TACP-3 clinical test with commercially available liquid body soap and water.
TACP-3 clinical trial design [I] No treatment - only water [J] Commercially available liquid body soap containing soybean oil
Attribute Evaluation Size ofSample Treatment Grouping * Averageadjusted Mistake-standard Degrees ofdrynessevaluatedby expert Base 47 [J] Soapliquid to thebody,commerciallyavailable,containing oilof soy The 2,769 0.073 46 [I] Nonetreatment -only water The 2,787 0.073
Petition 870180007766, of 01/29/2018, p. 78/88
4/77
Attribute Evaluation Size ofSample Treatment Grouping * Averageadjusted Mistake-standard Degrees ofdrynessevaluatedby expert 3 hoursafter thetreatment1 (1.3) 46 [J] Soapliquid to thebody,commerciallyavailable,containing oilof soy ab 2,719 0.090 45 [I] Nonetreatment -only water B 2,726 0.01 Attribute Evaluation Size ofSample Treatment Grouping * Averageadjusted Mistake-standard Degrees ofdrynessevaluatedby expert 3 hoursafter thetreatment5 (5.3) 44 [I] Nonetreatment -only water The 3.209 0.121 46 [J] Soapliquid to thebody,commerciallyavailable,containing oilof soy The 3,224 0. 118
[00199] Figure 8 shows the clinical hydration benefits of Inventive Example 32 versus Comparative Example 34 and a commercial product containing soybean oil. It is clear that Inventive Example 32 showed a significant reduction in skin dryness after 5 days versus Comparative Example 34 and the commercial product containing soybean oil. There are believed to be two main factors that contributed to the significant benefits: one factor is that the Inventive Examples are essentially free of sodium lauryl sulfate, which may have played a negative role in causing skin irritation in Comparative Example 34, and the second key factor is that the Example
Petition 870180007766, of 01/29/2018, p. 79/88
75/77
Inventive had higher lipid deposition due to the cationic polymer with optimal charge density (0.92 meq / g) versus the Comparative Example (0.7 meq / g). Both factors are believed to be important for the surprisingly high clinical efficacy of soy oil-containing compositions.
[00200] Exemplary formulations [00201] It is contemplated that other compositions, such as liquid hand soap, facial cleanser and hand dish washing soap, can be formulated with this invention. Exemplary formulations are mentioned below.
Compositions Example35(% Weight/Weight) Example36(% Weight/Weight) Example37(% Weight/Weight) Example38(% Weight/Weight) Example39(% Weight/Weight) Tridecet-2 sodium sulfate 7, 96 7, 96 6.50 7.55 7.55 Lauro sodium anfoacetate 2.35 2.35 1.92 - - Cocamido propyl betaine - - - 2.23 2.23 Tridecet-3 0.96 0.96 0.78 0.91 0.91 Guar hydroxy chloridepropyl triamonium 0.41 0.41 0.34 0.30 Cross polymeracrylates / alkyl acrylatesC10-C30 (Aqupec SER 300) 0.20 0.20 0.16 0, 19 0, 19 Sodium chloride 4.66 4.66 3.80 4.42 4.22 Citric acid / hydroxidesodium pH = 5.7 pH = 5.7 pH = 5.7 pH = 5.7 pH = 5.7 Petrolato 1.96 - - - - Glyceryl monooleate 0.04 - - - - Soy oil - 2 20 7.0 10 Water / preservatives / perfume q- ^s · q- ^s · q- ^s · q- ^s · q- ^s ·
[00202] The dimensions and values presented in the present invention should not be understood as being
Petition 870180007766, of 01/29/2018, p. 80/88
76/77 strictly limited to the exact numerical values mentioned. Instead, unless otherwise specified, each of these dimensions is intended to mean both the mentioned value and a range of functionally equivalent values around that value. For example, a dimension shown as 40 mm is intended to mean about 40 mm.
[00203] It should be understood that each maximum numerical limit mentioned in this specification includes each of the lower numerical limits, as if such lower numerical limits were expressly registered in this document. Each minimum numerical limit mentioned in this specification includes each of the upper numerical limits, as if such upper numerical limits were expressly registered in this document. Each number range mentioned in this specification includes each more restricted number range that is within that broader number range, as if such more restricted number ranges were expressly recorded in this document.
[00204] All the documents cited in the Detailed Description of the Invention are, in their relevant part, incorporated herein, for reference. The citation of any document should not be interpreted as an admission that it represents prior art with respect to the present invention. If there is a conflict between the meanings or definitions of terms mentioned in this document and the meaning or definition of terms in a document incorporated by reference, the meaning or definition assigned to a specific term mentioned in this document will take precedence.
[00205] Although particular embodiments of the present invention have been illustrated and described, it should be apparent to those skilled in the art that various other changes and modifications can be made without departing from the character and scope of the invention. Therefore, it is intended to cover
Petition 870180007766, of 01/29/2018, p. 81/88
77/77 claims attached all such changes and modifications that fall within the scope of the present invention.
Petition 870180007766, of 01/29/2018, p. 82/88
1/3

权利要求:
Claims (3)
[1]
1. Composition for personal care, characterized by comprising: at least one cleaning phase and one benefit phase, being that: said cleaning phase comprises:
a) an aqueous structured surfactant phase, comprising from 5% to 20%, by weight, of said composition for personal care, in STnS, where n is between 1 and 2,
b) at least one of the following: an amphoteric surfactant and a zwitterionic surfactant,
c) a structuring system comprising:
1. optionally, a non-ionic emulsifier, ii. from 0.05% to 5%, by weight, of said personal care composition, of an associative polymer comprising polyacrylates, hydrophobically modified polysaccharides, hydrophobically modified urethanes and / or mixtures thereof;
iii. an electrolyte, and the said benefit phase comprises:
d) from 0.1% to 50%, by weight, of said personal care composition, of a benefit agent, said personal care composition being, optionally, free of LSS, said composition for care personal structure comprises 70% or more lamellar.
[2]
Personal care composition according to claim 1, characterized in that the personal care composition comprises from 0.05% to 0.5%, by weight, of said personal care composition, in associative polymer.
Petition 870180007766, of 01/29/2018, p. 3/88
2/3
3. Composition for personal cares, according with claim 1, characterized by the said polymer associative understand a polymer of acrylate alkyl. 4. Composition for personal cares, according with claim 1, characterized per the said
nonionic emulsifier having a BHL of 3.4 to 13.0.
5. Personal care composition according to claim 4, characterized in that said nonionic emulsifier has a BHL of 3.4 to 8.0.
6. Personal care composition according to claim 1, characterized in that said nonionic emulsifier is selected from the group consisting of glyceryl monohydroxy, isostearet-2, tridecet-2, tridecet-3, hydroxystearic acid, stearate propylene glycol, PEG-2 stearate, sorbitan monostearate, glyceryl laurate, lauret-2, cocamide monoethanolamine, lauramide monoethanolamine and mixtures thereof.
7. Personal care composition according to claim 1, characterized in that the non-ionic emulsifier comprises one or more of the following: tridecet-2 and tridecet-3.
8. Personal care composition, according to claim 1, characterized in that said electrolyte is selected from the group consisting of sodium chloride, ammonium chloride, sodium sulfate, ammonium sulfate and mixtures thereof.
9. Personal care composition according to claim 1, characterized in that said benefit phase is anhydrous.
10. Personal care composition according to claim 1, characterized in that said benefit agent is selected from the group consisting of petrolatum, natural waxes, synthetic waxes,
Petition 870180007766, of 01/29/2018, p. 4/88
[3]
3/3 natural triglycerides, synthetic triglycerides, and combinations thereof.
11. Personal care composition according to claim 1, characterized in that said beneficial agent suitable for use in the present invention has a Vaughan solubility parameter in the
range of 10, 2 (J / cm ³ ) ^1/2 (5 (cal / cm ³ ) ^1/2 ) to: 30.7 (J / cm ³) ^1/2 (15 (cal / cm ³ )^1/2 ). 12. Composition for care personal, in according to claim 1, characterized by said benefit phase be free of surfactant. 13. Composition for care personal, in according to claim 1, characterized by n situ- between 1 and 2. 14. Composition for care personal, in according to claim 1, characterized per phase in aqueous structured surfactant comprise from 5% to 10% in STnS. 15. Use of the composition as defined in claims 1-14, characterized by improve The
stability.
Petition 870180007766, of 01/29/2018, p. 5/88
1/10 ogóniossip θρ iu®6e) U30JOd

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10588838B2|2020-03-17|Compositions for treating skin

---

CA2837105C|2016-08-23|Personal care compositions comprising sucrose polyesters

---

KR100681739B1|2007-02-15|Striped liquid personal cleansing compositions containing a cleansing phase and a separate benefit phase

---

CN107375035B|2021-04-20|Multiphase personal care compositions comprising a structuring system comprising an associative polymer, a low HLB emulsifier, and an electrolyte

---

US8105996B2|2012-01-31|Multiphase personal care composition comprising a structuring

---

EP2787966B1|2019-02-06|Personal care compositions

---

BRPI0818625B1|2016-02-10|personal care compositions comprising undecyl sulfates

---

US9364417B2|2016-06-14|Compositions for delivering perfume to the skin

同族专利:

---

公开号 | 公开日

---

MX348132B|2017-05-26|

---

MX2012014512A|2013-02-15|

---

US9750674B2|2017-09-05|

---

US20190167550A1|2019-06-06|

---

CA2800537C|2016-02-09|

---

US20170333315A1|2017-11-23|

---

BR112012031623A2|2016-08-23|

---

CN102933190A|2013-02-13|

---

US10588838B2|2020-03-17|

---

WO2011156672A2|2011-12-15|

---

WO2011156672A4|2012-05-31|

---

EP2579835A2|2013-04-17|

---

CN105919832A|2016-09-07|

---

WO2011156672A3|2012-04-05|

---

US20120009285A1|2012-01-12|

---

CA2800537A1|2011-12-15|

---

EP2579835B1|2020-06-24|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US2438091A|1943-09-06|1948-03-16|American Cyanamid Co|Aspartic acid esters and their preparation|

---

US2528378A|1947-09-20|1950-10-31|John J Mccabe Jr|Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same|

---

US2658072A|1951-05-17|1953-11-03|Monsanto Chemicals|Process of preparing amine sulfonates and products obtained thereof|

---

US3940351A|1974-07-02|1976-02-24|The B. F. Goodrich Company|Polymerization of carboxylic acid monomers and alkyl acrylate esters in chlorofluoroethane|

---

US3915921A|1974-07-02|1975-10-28|Goodrich Co B F|Unsaturated carboxylic acid-long chain alkyl ester copolymers and tri-polymers water thickening agents and emulsifiers|

---

US4062817A|1977-04-04|1977-12-13|The B.F. Goodrich Company|Water absorbent polymers comprising unsaturated carboxylic acid, acrylic ester containing alkyl group 10-30 carbon atoms, and another acrylic ester containing alkyl group 2-8 carbon atoms|

---

US4429097A|1982-09-16|1984-01-31|Rohm And Haas Company|Alkyl poly esters of acrylate oligomers and copolymers thereof for thickening purposes|

---

AT176396T|1987-10-22|1999-02-15|Procter & Gamble|LIGHT PROTECTION AGENTS CONTAINING CHELATE|

---

GB8813978D0|1988-06-13|1988-07-20|Unilever Plc|Liquid detergents|

---

JPH0395110A|1989-09-08|1991-04-19|Kanebo Ltd|Detergent composition|

---

US5011681A|1989-10-11|1991-04-30|Richardson-Vicks, Inc.|Facial cleansing compositions|

---

ES2148149T3|1990-04-26|2000-10-16|Procter & Gamble|CHELATING COMPOSITIONS INCLUDING ALPHA-DIAMINE COMPOUNDS.|

---

CA2079485C|1990-04-26|1999-05-11|Rodney Dean Bush|Chelator compositions comprising oxime compounds|

---

JPH0436224A|1990-05-31|1992-02-06|Kao Corp|Shampoo composition|

---

JP2895607B2|1990-10-12|1999-05-24|鐘紡株式会社|Transparent skin cosmetics|

---

GB2312264A|1993-09-06|1997-10-22|Uponor Ltd|Pipe fitting construction and method|

---

DK0730441T3|1993-11-12|2002-03-18|Procter & Gamble|Desquamation preparations containing salicylic acid and zwitterionic compounds|

---

US5681852A|1993-11-12|1997-10-28|The Procter & Gamble Company|Desquamation compositions|

---

US6068834A|1994-03-04|2000-05-30|The Procter & Gamble Company|Skin lightening compositions|

---

DE4416566A1|1994-05-11|1995-11-16|Huels Chemische Werke Ag|Aqueous viscoelastic surfactant solutions for hair and skin cleansing|

---

CA2192665C|1994-06-15|2001-12-18|Greg George Hillebrand|Methods of lightening hyperpigmented regions in mammalian skin|

---

US5939082A|1995-11-06|1999-08-17|The Procter & Gamble Company|Methods of regulating skin appearance with vitamin B3 compound|

---

US6150312A|1999-04-05|2000-11-21|Unilever Home & Personal Care Usa, A Division Of Conopco, Inc.|Liquid composition with enhanced low temperature stability comprising sodium tricedeth sulfate|

---

US20040235702A1|1999-07-17|2004-11-25|Huntsman International Llc|Structured surfactant systems|

---

US6635702B1|2000-04-11|2003-10-21|Noveon Ip Holdings Corp.|Stable aqueous surfactant compositions|

---

US6433061B1|2000-10-24|2002-08-13|Noveon Ip Holdings Corp.|Rheology modifying copolymer composition|

---

US6395691B1|2001-02-28|2002-05-28|Unilever Home & Personal Care Usa Division Of Conopco, Inc.|Personal wash compositions containing particle-in-oil dispersion|

---

US20020182112A1|2001-04-30|2002-12-05|Unilever Home & Personal Care Usa, Division Of Conopco, Inc.|In vivo method for measuring binding of chemical actives to skin or specific constituents of skin|

---

JP3851791B2|2001-09-04|2006-11-29|株式会社東芝|Semiconductor integrated circuit|

---

US6645511B2|2002-01-16|2003-11-11|Unilever Home & Personal Care Usa, Division Of Conopco, Inc.|Wet-skin treatment compositions|

---

US7288616B2|2002-01-18|2007-10-30|Lubrizol Advanced Materials, Inc.|Multi-purpose polymers, methods and compositions|

---

US6759376B2|2002-09-11|2004-07-06|Unilever Home & Personal Care Usa, Division Of Conopco, Inc.|Oil-containing personal wash liquid compositions or emulsions comprising particles of high refractive index and defined thickness, geometry and size|

---

US6780826B2|2002-09-11|2004-08-24|Unilever Home & Personal Care Usa, Division Of Conopco, Inc.|Oil-containing personal wash compositions or emulsions comprising particles of high refractive index and defined thickness, geometry and size|

---

JP4276179B2|2002-11-04|2009-06-10|ザプロクターアンドギャンブルカンパニー|Striped liquid personal cleansing composition having improved stability and containing a cleansing phase and a separate benefit phase|

---

US20040223991A1|2003-05-08|2004-11-11|The Procter & Gamble Company|Multi-phase personal care composition|

---

US20040223929A1|2003-05-08|2004-11-11|The Procter & Gamble Company|Personal care compositions containing hydrophobically modified interference pigments|

---

US20050100570A1|2003-05-08|2005-05-12|The Procter & Gamble Company|Multi-phase personal care composition|

---

US20050019299A1|2003-07-21|2005-01-27|Librizzi Joseph J.|Conditioning detergent compositions|

---

CN1832720B|2003-07-22|2010-05-12|罗迪亚公司|New branched sulfates for use in personal care formulations|

---

US7157414B2|2003-08-28|2007-01-02|J&J Consumer Companies, Inc.|Methods of reducing irritation in personal care compositions|

---

US20050049172A1|2003-08-28|2005-03-03|Lukenbach Elvin R.|Mild and effective cleansing compositions|

---

US20050075256A1|2003-08-28|2005-04-07|Joseph Librizzi|Methods of reducing irritation associated with personal care compositions|

---

US7119059B2|2003-08-28|2006-10-10|Johnson & Johnson Consumer Companies, Inc.|Mild and effective cleansing compositions|

---

US7084104B2|2003-08-28|2006-08-01|Johnson & Johnson Consumer Company Inc.|Mild and effective cleansing compositions|

---

US7098180B2|2003-08-28|2006-08-29|Johnson & Johnson Consumer Companies Inc.|Mild and effective cleansing compositions|

---

US20050143268A1|2003-11-14|2005-06-30|The Procter & Gamble Company|Personal care composition containing a cleansing phase and a benefit phase|

---

US7229778B2|2004-02-26|2007-06-12|The Procter & Gamble Company|Methods for determining the relative benefits and/or evaluating quantitative changes of products on epithelial tissue|

---

US20050276768A1|2004-06-14|2005-12-15|Karl Shiqing Wei|Multi-phased personal care composition|

---

DE602005026135D1|2004-08-19|2011-03-10|Colgate Palmolive Co|IMPROVED OIL LEAVING FROM STRUCTURED SURFACE FORMULATIONS|

---

US20060079420A1|2004-10-08|2006-04-13|Wagner Julie A|Multi-phase personal cleansing composition|

---

US20060079419A1|2004-10-08|2006-04-13|Julie Ann Wagner|Depositable solids|

---

US7666825B2|2004-10-08|2010-02-23|The Procter & Gamble Company|Stable, patterned multi-phased personal care composition|

---

US7531497B2|2004-10-08|2009-05-12|The Procter & Gamble Company|Personal care composition containing a cleansing phase and a benefit phase|

---

US20060079421A1|2004-10-08|2006-04-13|Wagner Julie A|Stable multi-phased personal care composition|

---

US8147853B2|2005-02-15|2012-04-03|The Procter & Gamble Company|Personal care compositions containing hydrophobically modified non-platelet particles|

---

US20060189495A1|2005-02-18|2006-08-24|Joseph Librizzi|Compositions with suspended particles|

---

US7527077B2|2005-02-25|2009-05-05|The Procter & Gamble Company|Multi-phase personal care compositions, processes for making and providing, and articles of commerce|

---

MX2007012898A|2005-04-13|2007-12-10|Procter & Gamble|Structured multi-phased personal care composition comprising branched anionic surfactants.|

---

CN101421007B|2005-05-10|2011-11-16|强生消费者公司|Low-irritation compositions and methods of making the same|

---

WO2006119981A1|2005-05-11|2006-11-16|Henkel Kommanditgesellschaft Auf Aktien|Low-residue deodorant or antiperspirant stick based on an oil-in-water dispersion/emulsion|

---

KR101351869B1|2005-05-20|2014-01-15|로디아 인코포레이티드|Structured surfactant compositions|

---

US8309667B2|2005-11-14|2012-11-13|Sumitomo Seika Chemicals Co., Ltd.|Water-soluble copolymer having alkyl-modified carboxyl groups|

---

US8067517B2|2005-11-21|2011-11-29|Sumitomo Seika Chemicals Co., Ltd.|Water-soluble copolymer having alkyl-modified carboxyl groups|

---

US20070196344A1|2006-01-20|2007-08-23|The Procter & Gamble Company|Methods for identifying materials that can help regulate the condition of mammalian keratinous tissue|

---

US20070224696A1|2006-02-27|2007-09-27|Honkonen Robert S|Metabonomic methods to assess health of skin|

---

EP2026880B1|2006-05-05|2018-07-04|Blaa Lonid Hf.|Pharmaceutical and cosmetic use of silica|

---

US8795679B2|2006-05-05|2014-08-05|Blaa Lonid Hf|Pharmaceutical and cosmetic use of extracts from algae obtainable from saline hot water sources|

---

US20070286832A1|2006-06-12|2007-12-13|Mannie Lee Clapp|Multi-phase personal cleansing compositions comprising two aqueous phases|

---

WO2008039440A1|2006-09-26|2008-04-03|Rhodia Inc.|Structured surfactant system|

---

US7803403B2|2006-11-09|2010-09-28|Johnson & Johnson Consumer Companies, Inc.|Low-irritation compositions and methods of making the same|

---

FR2908784B1|2006-11-17|2012-12-14|Oreal|COSMETIC USE OF A PROTEIN OF THE RIBONUCLEASE FAMILY|

---

EP2136768B1|2007-03-23|2018-10-17|Solvay USA Inc.|Structured surfactant compositions|

---

US8105996B2|2007-03-30|2012-01-31|The Procter & Gamble Company|Multiphase personal care composition comprising a structuring|

---

US8158566B2|2007-03-30|2012-04-17|The Procter & Gamble Company|Multiphase personal care composition comprising a structuring system that comprises an associative polymer, a low HLB emulsifier and an electrolyte|

---

FR2917629B1|2007-06-22|2009-09-11|Oreal|COSMETIC USE OF APOLIPOPROTEIN TYPE PROTEINS|

---

US20090005460A1|2007-06-29|2009-01-01|Gunn Euen T|Methods of making and using structured compositions comprising betaine|

---

US8518991B2|2007-06-29|2013-08-27|Johnson & Johnson Consumer Companies, Inc.|Structured compositions comprising betaine|

---

US9968535B2|2007-10-26|2018-05-15|The Procter & Gamble Company|Personal care compositions comprising undecyl sulfates|

---

FR2924613B1|2007-12-10|2012-12-21|Oreal|COSMETIC USE OF PROTEINS OF HSP27 TYPE.|

---

FR2924614B1|2007-12-10|2012-12-14|Oreal|COSMETIC USE OF CALGRANULIN A PROTEINS|

---

FR2924947B1|2007-12-18|2010-03-19|Oreal|COSMETIC USE OF CALMODULIN-LIKE SKIN PROTEIN CLSP PROTEINS|

---

FR2924946B1|2007-12-18|2010-02-26|Oreal|COSMETIC USE OF ACID CERAMIDASE-LIKE PROTEINS|

---

FR2925314B1|2007-12-19|2012-11-23|Oreal|COSMETIC USE OF TRANSGLUTAMINASE 3 PROTEINS|

---

FR2925313A1|2007-12-19|2009-06-26|Oreal|COSMETIC USE OF PLAKOGLOBIN PROTEINS|

---

FR2925312B1|2007-12-19|2016-12-02|Oreal|COSMETIC USE OF DESMOGLEINE I PROTEINS|

---

WO2010014614A2|2008-07-28|2010-02-04|The Procter & Gamble Company|Multiphase personal care composition with enhanced deposition|

---

DE102008035172A1|2008-07-28|2010-02-04|Henkel Ag & Co. Kgaa|Structured composition with optimal storage stability properties|

---

EP2524225B1|2010-01-17|2017-04-19|The Procter and Gamble Company|Biomarker-based methods for identifying and formulating compositions that improve skin quality and reduce the visible signs of aging in skin|

---

CA2763046A1|2009-06-18|2010-12-23|Qing Stella|Personal care composition comprising a synthetic cationic polymer|

---

EP2579835B1|2010-06-11|2020-06-24|The Procter and Gamble Company|Compositions for treating skin|

---

US9671410B2|2011-01-16|2017-06-06|The Procter & Gamble Company|Biomarker-based methods for identifying and formulating compositions that improve skin quality and reduce the visible signs of aging in skin|

---

BR112013031714B1|2011-06-10|2018-05-08|Procter & Gamble|personal care compositions|

---

US20130149273A1|2011-12-09|2013-06-13|The Procter & Gamble Company|Personal Care Compositions|

---

US9717674B1|2016-04-06|2017-08-01|The Procter & Gamble Company|Skin cleansing compositions comprising biodegradable abrasive particles|EP2579835B1|2010-06-11|2020-06-24|The Procter and Gamble Company|Compositions for treating skin|

---

EP2744340A2|2011-08-15|2014-06-25|The Procter and Gamble Company|Personal care methods|

---

US20130149273A1|2011-12-09|2013-06-13|The Procter & Gamble Company|Personal Care Compositions|

---

EP2827833A2|2012-03-22|2015-01-28|The Procter and Gamble Company|Personal care compositions and methods|

---

MX355080B|2012-04-20|2018-04-03|Procter & Gamble|Improving skin appearance with increase in skin chroma.|

---

EP2838615A1|2012-04-20|2015-02-25|The Procter and Gamble Company|Personal cleansing compositions|

---

US9622951B2|2012-10-29|2017-04-18|The Procter & Gamble Company|Personal care compositions|

---

CN109568166B|2012-12-14|2022-01-28|宝洁公司|Fragrance materials|

---

DE102013206314A1|2013-04-10|2014-10-16|Evonik Industries Ag|Cosmetic formulation containing copolymer as well as sulfosuccinate and / or biosurfactant|

---

US9101551B2|2013-10-09|2015-08-11|The Procter & Gamble Company|Personal cleansing compositions and methods|

---

US20150098920A1|2013-10-09|2015-04-09|The Procter & Gamble Company|Personal Cleansing Compositions and Methods|

---

US9687455B2|2014-08-14|2017-06-27|John Daniel Dobak|Sodium tetradecyl sulfate formulations for treatment of adipose tissue|

---

JP2017531469A|2014-09-26|2017-10-26|ザ プロクター アンド ギャンブルカンパニー|Products containing malodor reducing materials|

---

US10485739B2|2014-10-16|2019-11-26|Encapsys Llc|High strength microcapsules|

---

US9714397B2|2014-10-16|2017-07-25|Encapsys Llc|Controlled release microcapsules|

---

US9714396B2|2014-10-16|2017-07-25|Encapsys Llc|Controlled release dual walled microcapsules|

---

CN106999417A|2014-11-10|2017-08-01|宝洁公司|Personal cleaning compositions and method|

---

CN107106474B|2014-11-10|2021-06-01|宝洁公司|Personal care composition with two benefit phases|

---

EP3217950B1|2014-11-10|2020-01-29|The Procter and Gamble Company|Personal care compositions|

---

EP3217948B1|2014-11-10|2020-09-16|The Procter and Gamble Company|Personal care compositions with two benefit phases|

---

US10966916B2|2014-11-10|2021-04-06|The Procter And Gamble Company|Personal care compositions|

---

US9351945B1|2015-02-27|2016-05-31|John Daniel Dobak, III|Reduction of adipose tissue|

---

CA2977737C|2015-03-24|2020-08-18|The Procter & Gamble Company|Foam compositions, aerosol products, and methods of using the same to improve sensory benefits to the skin|

---

JP6875502B2|2016-09-19|2021-05-26|ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ|Effervescent compositions, aerosol products, and their use to improve sensory benefits to the skin|

---

EP3291790A1|2015-05-06|2018-03-14|The Procter and Gamble Company|Methods of cosmetically treating skin conditions with a cosmetic personal cleansing composition|

---

WO2017004282A1|2015-06-29|2017-01-05|Takasago Internation Corporation |Musk compositions and methods of use thereof|

---

CN108697599A|2016-03-24|2018-10-23|宝洁公司|Include the hair care composition of malodor reduction composition|

---

US9717674B1|2016-04-06|2017-08-01|The Procter & Gamble Company|Skin cleansing compositions comprising biodegradable abrasive particles|

---

WO2018049558A1|2016-09-13|2018-03-22|The Procter & Gamble Company|Methods of improving skin appearance|

---

EP3515397B1|2016-09-23|2021-06-23|The Procter & Gamble Company|Stable foam compositions and methods of using the same to provide enhanced sensory and visual benefits to skin|

---

WO2018057412A1|2016-09-23|2018-03-29|The Procter & Gamble Company|Foam compositions, aerosol products, and methods of using the same|

---

US10806692B2|2016-10-03|2020-10-20|The Procter & Gamble Company|Skin cleansing compositions comprising color stable abrasive particles|

---

US20180185255A1|2017-01-05|2018-07-05|The Procter & Gamble Company|Method of Selecting Mild Skin Cleansers|

---

DE102017217306A1|2017-09-28|2019-03-28|Beiersdorf Ag|Shower products with higher oil contents|

---

CN111212625A|2017-10-20|2020-05-29|宝洁公司|Aerosol foam skin cleaning agent|

---

CN111225652A|2017-10-20|2020-06-02|宝洁公司|Aerosol foam skin cleaning agent|

---

WO2019094913A2|2017-11-13|2019-05-16|The Procter & Gamble Company|Personal care composition|

---

EP3720568B1|2017-12-08|2022-01-12|The Procter & Gamble Company|Methods of screening for mild skin cleanser|

---

US10792384B2|2017-12-15|2020-10-06|The Procter & Gamble Company|Rolled fibrous structures comprising encapsulated malodor reduction compositions|

---

WO2021262439A2|2020-06-22|2021-12-30|The Procter & Gamble Company|Method for producing reduced glycol fatty alcohol ethoxylates, reduced glycol sulfate ethoxylated surfactants, and products|

法律状态:
2017-06-27| B07A| Technical examination (opinion): publication of technical examination (opinion)|

---

2017-06-27| B15K| Others concerning applications: alteration of classification|Ipc: A61K 8/19 (2006.01), A61K 8/02 (2006.01), A61K 8/3 |

---

2017-10-31| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law|

---

2018-02-06| B09A| Decision: intention to grant|

---

2018-04-10| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/06/2011, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US35411810P| true| 2010-06-11|2010-06-11|

---

US61/354,118|2010-06-11|

---

PCT/US2011/039907|WO2011156672A2|2010-06-11|2011-06-10|Compositions for treating skin|

---